Advertisement

C

  • F. von Bruchhausen
  • S. Ebel
  • A. W. Frahm
  • E. Hackenthal
  • Margitta Albinus
  • Hassan-Fahmy Ali
  • Syed Laik Ali
  • Gudrun Amschler
  • Uwe Amschler
  • Erwin von Angerer
  • Peter Barth
  • Wolfgang Barthel
  • Kurt Bauer
  • Andrea Bauer
  • Jürgen Beckmann
  • Winfried Beil
  • Jürgen Beitz
  • Günther Bellmann
  • Thorsten Beyrich
  • Franz Bossle
  • Helmut Bräunlich
  • Matthias Bräutigam
  • Kerstin Brinkmann
  • Adalbert Brinz
  • Franz von Bruchhausen
  • Kay Brune
  • Axel Büge
  • Ulrich Bürger
  • Wolfram Christ
  • Klaus Daneck
  • Gerd Dannhardt
  • Helga Doering
  • Siegfried Ebel
  • Kurt Eger
  • Peter Emig
  • Thomas Erker
  • Bernhard Feil
  • Monika Fett
  • August Wilhelm Frahm
  • Margarete Frahm
  • Klaus-Jürgen Freundt
  • Wolfram Gaida
  • Detlef Geffken
  • Ulrich Geis
  • Klaus Geldsetzer
  • Ulrich Gessner
  • Erika Glusa
  • Berthold Göber
  • Margarete Goppelt-Strübe
  • Wilhelm Gössling
  • Eberhard Gottwald
  • Beate Grates
  • Annette Graul
  • Sibylle Greiner
  • Adolf Grisk
  • Michael Grosam
  • Jan Gustafsson
  • Hartmut Gustmann
  • Jürgen Haas
  • Axel Haberkorn
  • Eberhard Hackenthal
  • Annette Häfner
  • Boris Haluszczynski
  • Achim Harder
  • Susanne Hartmann
  • Heribert Häusler
  • Marcus Heidenreich
  • Gerhard Heinemeyer
  • Bernd Hempel
  • Monika Herboth
  • Klaus Herbrand
  • Sibylle Hoedt-Schmidt
  • Wolfgang Hoefke
  • Hermann Hoffmann
  • Ute Hoffmann-Schollmayer
  • Bernhard Hofmann
  • Ulrike Holzgrabe
  • Anette Hornberger
  • Ute Hübner-Steiner
  • Martin Hug
  • Wolfgang Ibrom
  • Walter Janßen
  • Angela Jördens
  • Ilmar Jurna
  • Günther Kaiser
  • Dieter-Abbo Kalbhen
  • Petra Kisser
  • Christoph Klett
  • Stephanie Klett
  • Gerd Kobal
  • Johannes Koehler
  • Axel Kramer
  • Birgit Krammer
  • Gottfried Kreutz
  • Reinhard Kroker
  • Markus Kuhn
  • Norbert Kühn
  • Dorothea Landsiedel
  • Andreas Langner
  • Martina Laudszun
  • Jochen Lehmann
  • Marion Sylvia Lehner
  • Stefan Leiner
  • Hans Löwe
  • Johannes Mann
  • Detlef Manns
  • Wolfgang Matthiessen
  • Rainer Maue
  • Peter Maul
  • Andreas Maurer
  • Ralf Mayer
  • Wolfgang Meindl
  • Werner Meise
  • Klaus Menges
  • Paul Messinger
  • Hans-Jürgen Mest
  • Frank Peter Meyer
  • J. Mollière
  • Rudolf Morgenstern
  • Wolfgang Morick
  • Joachim Mössner
  • Alfred Müller
  • Walter E. Müller
  • Klaus Müller
  • Christa Müller
  • Daniel Müller
  • Michael Neugebauer
  • Ottmar Neugebauer
  • Peter Nickel
  • Peter Nuhn
  • Bernd Nürnberg
  • Joachim Oertel
  • Michael Oettel
  • Tilmann Ott
  • Thomas Otzen
  • Hartmut Oßwald
  • Peter Pachaly
  • Helmut Pelzer
  • Karl-Uwe Petersen
  • Siegfried Pfeifer
  • Klaus Pietrzik
  • Kathrin Pöllath
  • Olaf Queckenberg
  • Bernd Raffelsberger
  • Eberhard Reimann
  • Jörg Remien
  • Markus Reuß
  • Andreas Reymann
  • Joachim Richter
  • Peter H. Richter
  • Hubert Richter
  • Klaus Rittinghaus
  • Hans Rommelspacher
  • Gerhard Rücker
  • Gerhard Schaefer
  • Klaus Schaefer
  • Jutta Schcerer
  • Helmut Schlager
  • Hildegard Schleinitz
  • Wolfgang Schlichter
  • Gerhard Schmidt
  • Wolfgang Schmutzler
  • Johannes Schräder
  • Thomas Schulz-Schalge
  • Harald Schütz
  • Helmut Schwilden
  • Gisela Skopp
  • Ulrich Speck
  • Marcus Spohn
  • Ralf Stahlmann
  • Johannes-Peter Stasch
  • E. Staubli
  • Jürgen Steinmeyer
  • Karl-Heinz Stiefvater
  • Michael Streek
  • Günther Strippel
  • Karl-Heinz Surborg
  • Ulf Sürig
  • Istvan Szelenyi
  • Alfred Thomas
  • Herbert Trampisch
  • Reinhard Troschütz
  • Bernard Unterhalt
  • Eugen J. Verspohl
  • Sabine Vogel
  • Franz-Josef Volk
  • Sven Völkl
  • Heinz Walther
  • Horst Weber
  • Martin Wenzel
  • Marion Weyandt-Spangenberg
  • Sandra Wich
  • Burkhard Wichert
  • Hilke Winterhoff
  • Peter Witte
  • Monika Wolff

References

KC

  1. 1.
    BAz, Nr. 22a vom 03.02.1988 GsGoogle Scholar

References

  1. 1.
    Roth L, Daunderer M (1990) Toxikologische Enzyklopädie, Giftliste Bd. III, S. 5Google Scholar

Eb/SK

  1. 1.
    BAz, Nr. 22a vom 03.02.1988Google Scholar

GS

  1. 1.
    Patent Ger.Offen. 1,938,016 (Cl.C07d,A61k) 1971, zit. nach CA 74:88064kGoogle Scholar
  2. 2.
    Klosa J (1962) J Prakt Chemie 17:331–339CrossRefGoogle Scholar
  3. 3.
    Kuhnert-Brandstätter M, Bösch L, Eckstein G (1978) Sci Pharm 46:54–61Google Scholar
  4. 4.
    Krácmar J et al (1989) Pharmazie 44:768–771Google Scholar
  5. 5.
    Bähring SR et al (1975) Drugs of Today 11:365–368Google Scholar

LD

  1. 1.
    Leypoldt R (1976) Therapiewoche 26:3381–3384Google Scholar
  2. 2.
    Walter H, Köhler E (1979) Pharmazie 34:375–376Google Scholar
  3. 3.
    CorstenM(1975) Ärztl Prax 97:3.911–3.913Google Scholar
  4. 4.
    Alschner G (1979) Medicamentum 51:16–19Google Scholar
  5. 5.
    Volta F (1982) Medicamentum 60:24–25Google Scholar

Mt

  1. 1.
    DBP 1095285 (1956) (Degussa; Erf. Kohlstädt E, Klingler KH); Brit 859445 (1956); (Chemiewerk Homburg; 25.01.1961), zit. nach CA (1961) 55:14489dGoogle Scholar
  2. 2.
    Klingler KH, Engel J, Lüderwald I (1980) Arzneim Forsch 30 (7):1060–1064Google Scholar
  3. 3.
    Daldrup T, Susanto F, Michalke P (1981) Fresenius’Z Anal Chem 308 (5):413–427CrossRefGoogle Scholar
  4. 4.
    Käferstein H, Sticht G (1986) Beitr Gerichtl Med 44:253–261PubMedGoogle Scholar

NE

  1. 1.
    Mar 28, S 1688Google Scholar

Mt

  1. 1.
    Klingler KH, Engel J, Lüderwald I (1980) Arzneim Forsch 30(7):1060–1064Google Scholar
  2. 2.
    DBP 1.095.285 (1956) (Degussa; Erf. Kohlstädter E, Klingler KH);Brit 859.445 (1956); (Chemiewerk Homburg; 25.1.1961); (CA (1961) 55:14.489d)Google Scholar
  3. 3.
    Kracmar J, Kracmarova J, Bokovikova TN, Ciciro VE, Nesterova GA, Suranova AV, Trius NV (1989) Pharmazie 44(11):768–771Google Scholar

NE

  1. 1.
    Bernasconi R, Mühlemann H (1967) Pharm Act Helv 42:234–255Google Scholar

WS

  1. 1.
    Blunt JW, DeLuca HF (1969) Biochemistry 8:671–675PubMedCrossRefGoogle Scholar
  2. 2.
    Dibbern HW (Hrsg.) (1984) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Canter, AulendorfGoogle Scholar
  3. 3.
    Blunt JW, DeLuca HF, Schnoes HK (1968) Biochemistry 7:3317–3322PubMedCrossRefGoogle Scholar
  4. 4.
    Vanhaelen-Fastre R, Vanhaelen M (1979) J Chromatogrl79(l):131–142CrossRefGoogle Scholar

KU

  1. 1.
    Hepner GW, Jowsey J, Arnaud C, Gordon S, Black J, Roginsky M, Moo HF, Young JF (1978) Am J Med 65:1.015–1.020Google Scholar
  2. 2.
    Sitrin MD, Bengoa JM (1987) Am J Clin Nutr 46:1.011–1.015Google Scholar
  3. 3.
    Haddad JG, Rojanasathit S (1976) J Clin Endocrinol Metab 42:284–290PubMedCrossRefGoogle Scholar
  4. 4.
    Bec PH, Bayard F, Louvet JP (1972) Rev Europ Etudes Clin et Biol 17:793–796Google Scholar

bm

  1. 1.
    Cooper CW, Peng TC, Obie JF (1980) Endocrinology 107:98–107PubMedCrossRefGoogle Scholar
  2. 2.
    Fischer JA, Tobler PH, Kaufmann M, Born W, Henke H, Cooper PE, Sagart SM, Martin JB (1981) Proc Natl Acad Sci 78:7.801–7.805CrossRefGoogle Scholar
  3. 3.
    Flynn JJ, Margules DL, Cooper CW (1981) Brain Res Bull 6:547–549PubMedCrossRefGoogle Scholar
  4. 4.
    Maclntyre I, Alevizaki M, Brevis PJR, Zaidi M (1987) Clin Orthop 217:45–55Google Scholar
  5. 5.
    Azria M (1989) The calcitonins: Physiology and Pharmacology, Karger Basel München Paris London New York New Delhi Singapore Tokyo SydneyGoogle Scholar
  6. 6.
    Haas HG, Dambacher MA, Guncaga J, Lauffenburger C (1971) J Clin Invest 50:2.689CrossRefGoogle Scholar
  7. 7.
    Bijvoit OLM, van der Sluys Veer J, Jansen AP (1968) LancetI:876CrossRefGoogle Scholar
  8. 8.
    Guttmann S (1983) Distribution of calcitonins between their receptors and antibodies. In: The effects of calcitonin in man, Proc 1st int Wkshp, Florence 1982, Ed Gennari C, Segre G, Masson, S. 25–31Google Scholar
  9. 9.
    Olgiati VR, Guidobono F, Netti C, Pecile A (1983) Brain Res 265:209–215PubMedCrossRefGoogle Scholar
  10. 10.
    Chabardes D, Gagnan-Brunette M, Imbert-Teboul M, Gontcharevskaia O, Montegut M, Clipue A, Morel F (1980) J Clin Invest 65:439–448PubMedCrossRefGoogle Scholar
  11. 11.
    Chabardes D, Imbert-Teboul M, Montegut M, Clipue A, Morel F (1976) Proc Natl Acad Sci 73:3.608–3.612CrossRefGoogle Scholar
  12. 12.
    Hirsch PF, Numson PL (1969) Physiol Rev 49:548–622PubMedGoogle Scholar
  13. 13.
    Doepfner WEH (1983) Pharmacological effects of calcitonin. Triangle, The Sandoz Journal of Medical Science 22:57–67Google Scholar
  14. 14.
    Reynolds JJ, Dingle JT (1970) Calcif Tissue Res 4:339–349PubMedCrossRefGoogle Scholar
  15. 15.
    Raisz LG, Niemann I (1967) Nature 214:486–487PubMedCrossRefGoogle Scholar
  16. 16.
    Maclntyre I, Parsons JA, Robinson CJ (1967) J Physiol Lond 191:393–405Google Scholar
  17. 17.
    Holtrop ME, Raisz LG (1979) Clacif Tissue Int 29:201–205CrossRefGoogle Scholar
  18. 18.
    Hosking DJ, Vennart W, Huddlestone LB (1981) Calcif Tissue Res 33:471–476CrossRefGoogle Scholar
  19. 19.
    Holtrop ME, Raisz LG, Simmons HA (1974) J Cell Biol 60:246–355CrossRefGoogle Scholar
  20. 20.
    Hioco D (1969) Prolonged administration of calcitonin in man: Biological, isotopic and morphological effects. In: Calcitonin 1969, Proc 2nd in Symp, London, Taylor S, Foster G (Hrsg.), Heinemann 1970:514–522Google Scholar
  21. 21.
    Lesh HB (1973) Clinical experience with procine and salmon calcitonin, Endocrinology, Proc 46h Int Symp, Taylor S (Hrsg.), Heinemann 1974:409–424Google Scholar
  22. 22.
    Singer FR, Melvin KE, Mills BG (1976) Clin Endocrinol (Oxf) Suppl5:333S–340SCrossRefGoogle Scholar
  23. 23.
    Epstein S, Poser J, McClintock R, Johnston CCJr, Bryce G, Hui S (1984) Lancet 1:307–310PubMedCrossRefGoogle Scholar
  24. 24.
    Minaire P Calcitonin treatment of acute osteoporosis resulting from paraplegia. In: Calcitonin 1984, selected short communications presented at Int Symp Milan 1984; Doepfner WEH (HRsg.) Excerpta Medica 1986, Curr Clin Prac Series 42:111–118Google Scholar
  25. 25.
    Toccafondi R Biological effects of salmon calcitonin in osteoblast-like cells. In: Calcitonin-Chemistry, Physiology, Pharmacology and Chemical Aspects, Proc Int Symp, Milan 1984, Pecile A (Hrsg.) Excerpta Medica 1985, Int Cong Ser 663:197–204Google Scholar
  26. 26.
    Delloing G (1970) The effect of calcitonin on fracture healing and ectopic bone formation in the rat. In: Calcitonin 1969, Proc 2nd Int Symp, London 1969, Taylor S, Foster G (Hrsg.), Heinemann, S. 175–181Google Scholar
  27. 27.
    Williams CP, Meachim G, Taylor WH (1978) J Clin Pathol 31:1.212–1.217Google Scholar
  28. 28.
    Glowacki J, Deftos LJ (1983) The effects of calcitonin on bone formation. In: The effects of calcitonin in man, Proc 1st Int Wkshp, Florence 1982, Gennari C, Segre G (Hrsg.), Masson, S. 133–140Google Scholar
  29. 29.
    Ardaillou R, Vuagnat P, Milhaud G, Richet G (1967) Nephron 4:298–314PubMedCrossRefGoogle Scholar
  30. 30.
    Langer B, Peytremann A, Rufener C, Jenny M (1971) Schweiz Med Wochenschr 101:69–80PubMedGoogle Scholar
  31. 31.
    Williams CC, Matthews EW, Moseley JM, Maclntyre I (1972) Clin Sci 41:129–137Google Scholar
  32. 32.
    Carney S, Thompson L (1981) Am J Physiol 240:F12–F16PubMedGoogle Scholar
  33. 33.
    Ziegler R, Minne H, Hotz J, Goebell H (1974) Digestion 11:157–160PubMedCrossRefGoogle Scholar
  34. 34.
    HotzJ,GoebellH(1976)ZGastroenterol(Verh):71–77Google Scholar
  35. 35.
    Iwatsuki K, Hashimoto K (1976) Clin Exp Pharmacol Physiol 3:159–165PubMedCrossRefGoogle Scholar
  36. 36.
    Goebell H, Hotz J (1976) Inhibition of pancreatic secretion of enzymes by calcitonin. In: Effects of calcitonin and somatostatin on gastrointestinal tract and pancreas, Goevell H, Hotz J (Hrsg.), Demeter Verlag, S. 28–31Google Scholar
  37. 37.
    Paul F, Neumann F, Huchzermeyer H (1978) Scand J Gastroenterol 13:959–967PubMedCrossRefGoogle Scholar
  38. 38.
    Doepfner WEH, Briner U (1981) Calcitonin and gastric secretion. In: Calcitonin 1980, Proc int Symp, Milan 1980, Pecile A (Hrsg.), Excerpta Medica 1981, Int Cong Ser 540:123–135Google Scholar
  39. 39.
    Doepfner W, Buiner U, Ohnhaus E (1976) Effects of synthetic salmon calcitonin on gastric secretion and ulcer formation in conscious cats and rats. In: Effects of calcitonin and somatostatin on gastrointestinal tract and pancreas, Goebell H, Hotz J (Hrsg.), Demeter Verlag, S. 60–70Google Scholar
  40. 40.
    Ziegler R, Bellwinkel S, Schmidtchen D, Minne H (1972) Horm Metab Res 4:60PubMedCrossRefGoogle Scholar
  41. 41.
    Gattereau A, Bielmann P, Durivage J, Davignon J, Larochelle P (1980) J Clin Endocrinol Metab 51:354–357PubMedCrossRefGoogle Scholar
  42. 42.
    Paul F, Ohnhaus EE, Hesch RD, Chenmitz G, HoppeSeyler R, Herichs HR, Hartung H, Walsmann D, Kunze K, Barth E, Nüesch E, Abt K (1979) Dtsch Med Woenschr 104:615–622CrossRefGoogle Scholar
  43. 43.
    Goebell H, Hotz J (1981) Calcitonin, pancreatic secretion and pancreatitis. In: Calcitonin 1980, Proc int Symp, Milan 1980, Pecile A (Hrsg.), Excerpta Medica 1981, Int Cong Ser 540:346–351Google Scholar
  44. 44.
    Welzel D (1983) Analgesic potential of salmon calcitonin in postoperative pain. In: The effects of calcitonin in man, Proc 1st int Wkshp, Florence 1982, Gennari C, Segre G (Hrsg.), Masson, S. 223–232Google Scholar
  45. 45.
    Braga P, Ferri S, Santagostino A, Olgiati VR, Pecile A (1978) Life Sci 22:971–977PubMedCrossRefGoogle Scholar
  46. 46.
    Segre G (1983) Non-traditional activities of calcitonin. In: The effects of calcitonin in man, Proc 1st int Wkshp, Florence 1982, Gennari C, Segre G (Hrsg.), Masson, S. 55–64Google Scholar
  47. 47.
    Ceserani R, Colombo M, Olgiati VR, Pecile A (1979) Life Sci 25:1.851–1.855CrossRefGoogle Scholar
  48. 48.
    Gennari C (1981) Calcitonin and bone metastases of cancer. In: Calcitonin 1980, Proc int Symp, Milan 1980,Pecile A (Hrsg.), Excerpta Medica 1981, Int Cong Ser 540:227–287Google Scholar
  49. 49.
    Nüesch E, Schmidt R (1981) Comparative pharmacokinetics of calcitonins. In: Calcitonin 1980, Proc int Symp, Milan 1980, Pecile A (Hrsg.), Excerpta Medica 1981, Int Cong Ser 540:532–564Google Scholar
  50. 50.
    Beveridge T, Niederer W, Nüesch E, Petrin A (1976) Z Gastroenterol (Verh) 10:12–15Google Scholar
  51. 51.
    Huwyler R, Born W, Ohnhaus EE, Fischer JA (1979) Am J Physiol 236:E15–E19PubMedGoogle Scholar
  52. 52.
    Ardaillou R, Paillard F, Sraer J, Vallee G (1973) Horm Metab Res 5:232–233PubMedCrossRefGoogle Scholar
  53. 53.
    Riggs BL, Arnaud CD, Goldsmith RS, Taylor WF, McCall JT, Sessler AD (1971) J Clin Endocrinol Metab 33:115–127 WIPubMedCrossRefGoogle Scholar

WI

  1. 1.
    Halket JM, Liboa BP (1978) Acta Endocrinol 87 (Suppl 125):120Google Scholar
  2. 2.
    Flann BC, Lodge BA (1986) J Assoc Off Anal Chem 69(6):1026–1030, zit. nach CA (1987) 106:38562ePubMedGoogle Scholar
  3. 3.
    Vanhaelen-Fastre R, Vanhaelen M (1979) J Chromatogrl79(l):131–142Google Scholar
  4. 4.
    Hartke K, Mutschier E (Hrsg.) (1986) Kommentar zum Deutschen Arzneibuch 9. Ausg., Bd. 1–3, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S.3985Google Scholar

KU

  1. 1.
    Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW (1990) Am J Kidney Dis 16:126–132PubMedGoogle Scholar
  2. 2.
    Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O (1991) Clin Nephrol 35:72–77PubMedGoogle Scholar
  3. 3.
    Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW (1985) J Lab Clin Med 105:239–246PubMedGoogle Scholar
  4. 4.
    Gray RW, Caldas AE, Wilz DR, Lemann J, Smith GA, DeLuca HF (1978) J Clin Endocrinol Metab 46:756–765PubMedCrossRefGoogle Scholar
  5. 5.
    Mawer EB, Backhouse J, Davies M, Hill LF, Taylor CM (1976) Lancet 1:1.203–1.206Google Scholar
  6. 6.
    Glorieux FH (1990) Metabolism 39(Suppl. 1):10–12PubMedCrossRefGoogle Scholar
  7. 7.
    Pols HAP, Birkenhäger-Frenkel DH, Birkenhäger JC (1989) Neth J Med 35:108–118PubMedGoogle Scholar
  8. 8.
    Feinfeld DA, Sherwood LM (1988) Kidney Int 33:1.049–1.058CrossRefGoogle Scholar
  9. 9.
    Baker LRI, Abrams SML, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH (1989) Kidney Int 36(Suppl.27):140–142Google Scholar
  10. 10.
    Sherwood LM, Russell J (1989) Proc Soc Exp Biol Med 191:233–237PubMedGoogle Scholar
  11. 11.
    Riggs BL (1990) Metabolism 39(Suppl. l):1–2PubMedCrossRefGoogle Scholar
  12. 12.
    Gallagher JC, Riggs BL (1990) Metabolism 39(Suppl. l):30–34PubMedCrossRefGoogle Scholar
  13. 13.
    Tilyard MW, Spears GFS, Thomson J, Dovey S (1992) N Engl J Med 326:357–362PubMedCrossRefGoogle Scholar
  14. 14.
    Ott SM, Chesnut III CH (1989) Ann Intern Med 110:267–274PubMedCrossRefGoogle Scholar
  15. 15.
    Czarnetzki BM(1989) Dermatologica 178:184–188PubMedCrossRefGoogle Scholar
  16. 16.
    Kragballe K, Gjertsen BT, De Hoop D, Karlsmark T, Van De Kerkhof PCM, Larkö O, Nieboer C, RoedPetersen J, Strand A, Tikjøb G (1991) Lancet 337:193–196PubMedCrossRefGoogle Scholar
  17. 17.
    Sweet DV (1987) (Hrsg.) Registry of toxic effects of chemical substances, Bd. 2, U.S. Department of Health and Human Services, Washington, S. 1.577–1.578 (Nr. 25.664)Google Scholar

bm

  1. 1.
    BAz, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    BAz, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    BAz, Nr. 109a vom 16.06.1987 i.d.F. vom BAz, Nr.2 vom 06.01. 1993Google Scholar

GS

  1. 1.
    BAz, Nr. 109a om 16.06.1987Google Scholar

GS

  1. 1.
    BAz, Nr. 190a vom 10.10.1985 i.d.F. vom BAz, Nr. 47 vom 08.03.1990Google Scholar

GS

  1. 1.
    BAz, Nr. 109a om 16.06.1987Google Scholar

GS

  1. 1.
    BAz, Nr. 190a vom 10.10.1985Google Scholar

GS

  1. 1.
    BAz, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    Gmelin’s Handbuch der Anorganischen Chemie (1956), Calcium, System-Nr.28B, 8. Aufl., Verlag Chemie, Weinheim, S. 102Google Scholar
  2. 2.
    Loc.cit.(1957),28B,S.610fGoogle Scholar
  3. 3.
    Loc.cit.(1957),28B,S.615Google Scholar

WS

  1. 1.
    BAz, Nr. 190a vom 10.10.1985 i.d.F. vom BAz, Nr. 16 vom 24.01.1989Google Scholar

GS

  1. 1.
    BAz, Nr. 129a vom 15.07.1988Google Scholar

GS

  1. 1.
    BAz, Nr. 190a vom 10.10.1985Google Scholar

GS

  1. 1.
    BAz, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    BAz, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    B Az, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    B Az, Nr. 190a vom 10.10.1985Google Scholar

GS

  1. 1.
    Sanders DC (1985) Bromine Compounds. In: Gerhartz W (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Band A4, VCH Verlagsgesellschaft, Weinheim, S. 424Google Scholar
  2. 2.
    Gmelin’s Handbuch der Anorganischen Chemie (1956) Calcium, System Nr. 28B, 8. Aufl., Verlag Chemie, Weinheim, S. 584 f.Google Scholar
  3. 3.
    Falbe J, Regitz M (Hrsg.) Römpp Chemie Lexikon, 9. Aufl., G. Thieme Verlag, Stuttgart, S.551Google Scholar

WS

  1. 1.
    Gundlach H Kalk. In: Ull Bd. 13, S. 498 ffGoogle Scholar
  2. 2.
    Brückner H (1953) Calcium und -Verbindungen. In: Ulimanns Enzyklopädie der technischen Chemie, 3. Aufl.,Bd.4,S.836ffGoogle Scholar

ws/SH

  1. 1.
    Walther C, Holtermüller KH (1983) Z Gastroenterol (Suppl.) 21:7–14PubMedGoogle Scholar
  2. 2.
    Holtermüller KH (1979) Med Mo Pharm 2:354–360Google Scholar
  3. 3.
    Gugler R (1982) Klinische Pharmakologie der Antazida. In: Halter F (Hrsg.) Antazida, Urban & Schwarzenberg, Müchen Wien Baltimore, S. 7–19Google Scholar
  4. 4.
    Herzog P, Holtermüller KH (1982) Scand J Gastroentol (Suppl.) 75:56–62Google Scholar
  5. 5.
    Ginsburg DS, Kaplan AL, Katz AI (1973) Lancet 1:1.271–1.274Google Scholar
  6. 6.
    Weingart J, Kunert H (1981) Forschr Med 99:278–282Google Scholar
  7. 7.
    Ottenjann R, Kunert H, Weingart J, Höchter W (1983) Z Gastroenterol (Suppl.) 21:74–80PubMedGoogle Scholar
  8. 8.
    Holland D, Harlan J (1973) JAMA 226:1.1818–1.185Google Scholar
  9. 9.
    Ewe K (1983) Z Gastroenterol (Suppl.) 21:53–58PubMedGoogle Scholar
  10. 10.
    Weihrauch TR (1983) Z Gastroenterol (Suppl.) 21:50–52PubMedGoogle Scholar
  11. 11.
    Fordtran JS (1968) N Engl J Med 279:900–905PubMedCrossRefGoogle Scholar
  12. 12.
    Holtermüller KH, Sinterhauf K, Büchler R (1975) Verh Dtsch Ges Inn Med 81:1.237–1.239Google Scholar
  13. 13.
    Holtermüller KH, Malagelada JR, Mc Call JT, Go VLW (1976) Gastroenterology 70:693–696PubMedGoogle Scholar
  14. 14.
    Stiel JN, Mitchell CA, Racliff FJ, Piper DW (1967) Gastroenterology 52:900–904Google Scholar
  15. 15.
    Texter EC, Laureta HC (1966) Am J Dig Dis 11:413–418PubMedCrossRefGoogle Scholar
  16. 16.
    Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen DA (1978) Clin Pharmacol Ther 24:308–315PubMedGoogle Scholar
  17. 17.
    Rivera-Calimlin L, Dujoune CA, Morgan JO, Lasagna L, Bianchine JR (1971) Europ J Clin Invest 1:313–318CrossRefGoogle Scholar
  18. 18.
    Gugler R, Masch E (1983) Z Gastroenterol (Suppl.) 21:127–133PubMedGoogle Scholar
  19. 19.
    Ekenved G, Halvorsen L, Sölwell L (1976) Scand J Haematol (Suppl.) 28:65–77Google Scholar
  20. 20.
    Hurwitz A (1977) Clin Pharmacokinet 2:269–280PubMedCrossRefGoogle Scholar

Wb

  1. 1.
    Hollemann-Wiberg (1985), Lehrbuch der anorganischen Chemie 91.bis 100. Aufl., Verlag W. de Gruyter. S.914Google Scholar

SH

  1. 1.
    Tanc L, Israel M, Pichon Y, Simonneau M, Stinnakre J (1980) J Physiol 76:383–527Google Scholar
  2. 2.
    Norman AW (1977) Vitamin D, biochemical, chemical and clinical aspects related to calcium metabolism Walter de Gruyter, BerlinGoogle Scholar
  3. 3.
    Hauschild F (1960) Pharmakologie und Grundlagen der Toxikologie, Thieme Verlag, LeipzigGoogle Scholar
  4. 4.
    Ahnefeld FW, Schmitz JE (1980) Systematisierung von Infusionslösungen und Grundlagen der Infusionstherapie, Karger Verlag, BaselGoogle Scholar
  5. 5.
    Seifart W (1976) Kurzer Leitfaden der praktischen Infusionstherapie, Fischer Verlag, StuttgartGoogle Scholar
  6. 6.
    Kuemmerle HP, Goossens N (1978) Klinik und Therapie der Nebenwirkungen, Thieme Verlag, StuttgartGoogle Scholar

bh

  1. 1.
    Cole GM US Pat (1945) 2,389,766, zit. nach CA (1946) 40:5757/5Google Scholar

Ws

  1. 1.
    Hauschild F (1960) Pharmakologie und Grundlagen der Toxikologie, Thieme Verlag, LeipzigGoogle Scholar
  2. 2.
    Estler CJ (1983) Lehrbuch der allgemeinen und systematischen Pharmakologie und Toxikologie, Schattauer Verlag, Stuttgart New YorkGoogle Scholar
  3. 3.
    Lang F (1980) Klin Wschr 59:985–1.003CrossRefGoogle Scholar
  4. 4.
    Norman AW (1977) Vitamin D, biochemical, chemical and clinical aspects related to calcium metabolism, Walter de Gruyter, BerlinGoogle Scholar

bh

  1. 1.
    Boehringer CH, Schneider H, Weyland P (1942) DP Nr. 761525Google Scholar

Et

  1. 1.
    Haas H, Phosphoroxide, Phosphorsäuren und Phosphate. In: Ull, Bd. 18, S. 333 2. Jensen AT, Rathiev J (1953) Inorg Synth 4:18–22Google Scholar

WS

  1. 1.
    Turczan JW, Goldwitz BA, Medwick T (1977) J Agric Food Chem 25:594–602PubMedCrossRefGoogle Scholar
  2. 2.
    Sveshnikov BY (1940) J Applied Chem 13:762–768Google Scholar
  3. 3.
    Smelik J, Zeiser O (1953) Österr Chem Ztg 54:180–182Google Scholar

MA

  1. 1.
    Lang F (1980) Klin Wschr 58:985–1.003PubMedCrossRefGoogle Scholar
  2. 2.
    Rasmussen H (1971) Intern Encyclop Pharmacol Therap Sect 51, Pergamon Press, OxfordGoogle Scholar
  3. 3.
    Hauschild F (1960) Pharmakologie und Grundlagen der Toxikologie, Thieme Verlag, LeipzigGoogle Scholar
  4. 4.
    Hornbostel H, Kaufmann W, Siegenthaler W (1977) Innere Medizin in Praxis und Klinik, Thieme Verlag, StuttgartGoogle Scholar

bh

  1. 1.
    Udupa HV, Udupa KS, Subbiah P, Jayaraman K, Balakrishnan TD, Thirunavukkarasu P (Council of Scientific and Industrial Research (India)) Indian IN 154.413 (CLC 13k 5/00) 1984 Appl.80/DE 505; 1980, 13pp; CA (1986) 104:26.212mGoogle Scholar

ws

  1. 1.
    Hauschild F (1960) Pharmakologie und Grundlagen der Toxikologie, Thieme Verlag, LeipzigGoogle Scholar
  2. 2.
    Estler CJ (1983) Lehrbuch der allgemeinen und systematischen Pharmakologie und Toxikologie, Schattauer Verlag, Stuttgart New YorkGoogle Scholar
  3. 3.
    Fülgraff G, Palm D (1989) Pharmakotherapie, Klinische Pharmakologie, Fischer Verlag, Stuttgart New YorkGoogle Scholar
  4. 4.
    Hornbostel H, Kaufmann W, Siegenthaler W (1977) Innere Medizin in Praxis und Klinik, Thieme Verlag, StuttgartGoogle Scholar

bh

  1. 1.
    Nieper HA (1969) ZA Pat 6807124, zit. nach CA 71:105211pGoogle Scholar

WS

  1. 1.
    Schabacher W, Fluor und anorganische Fluor-Verbindungen. In: Ull, Bd. 11, S. 603ffGoogle Scholar
  2. 2.
    Gmelin’s Handbuch der Anorganischen Chemie (1956) Calcium, System-Nr. 28B, 8. Aufl., Verlag Chemie, Weinheim, S. 70fGoogle Scholar

WS

  1. 1.
    Mar 29, S. 1.551Google Scholar

vB

  1. 1.
    MI10 2. Kle 82Google Scholar

SH

  1. 1.
    Davis RE (1986) Adv Clin Chem 25:233–294PubMedCrossRefGoogle Scholar
  2. 2.
    Jolivet J (1988) Rescue therapy in methotrexate treatment: An overview. In: Erlichman C (Hrsg.) Leucovorin: An expanding role in chemotherapy, Pharma Libri Publishers, Montreal, S. 15–32Google Scholar
  3. 3.
    Bleyer A (1989) Cancer 63:995–1007PubMedCrossRefGoogle Scholar
  4. 4.
    Rustum YM, Campbell JF (1988) Metabolic modulation of fluorouracil by leueovorin: Biochemical rationale and clinical implications. In: Erlichman C (Hrsg.) Leueovorin: An expanding role in chemotherapy, Pharma Libri Publishers, Montreal, S. 3–14Google Scholar
  5. 5.
    Moran RG (1989) Cancer 63:1008–1012CrossRefGoogle Scholar
  6. 6.
    Mini E, Trave F, Rustum YM, Bertino JR (1990) Pharmac Ther 47:1–19CrossRefGoogle Scholar
  7. 7.
    Schalhorn A (1988) Clinical pharmacology of folinic acid and 5-fluorouracil. In: Erlichman C (Hrsg.) Leueovorin: An expanding role in chemotherapy, PharmaLibri Publishers, Montreal, S. 33–50Google Scholar

Fk

  1. 1.
    l.Mar29,S.1029Google Scholar

vB

  1. 1.
    Estler CJ (1983) Lehrbuch der allgemeinen und systematischen Pharmakologie und Toxikologie, Schattauer Verlag, Stuttgart New YorkGoogle Scholar
  2. 2.
    Tauc L, Israel M, Pichou Y, Simonneau M, Stinnakre J (1980) J Physiol 76:383–527Google Scholar
  3. 3.
    Hauschild F (1960) Pharmakologie und Grundlagen der Toxikologie, Thieme Verlag, LeipzigGoogle Scholar
  4. 4.
    Köhler G (1988) Lehrbuch der Homöopathie, Hippokrates Verlag, StuttgartGoogle Scholar
  5. 5.
    Lang F (1980) Klin Wschr 58:985–1.003PubMedCrossRefGoogle Scholar
  6. 6.
    Kuemmerle HP, Goossens N (1978) Klinik und Therapie der Nebenwirkungen, Thieme Verlag, StuttgartGoogle Scholar
  7. 7.
    Fülgraff G, Palm D (1989) Pharmakotherapie-Klinische Pharmakologie, Fischer Verlag Stuttgart New YorkGoogle Scholar
  8. 8.
    Minne HW (1988) Apotheker Journal H 9:46–48Google Scholar
  9. 9.
    Glatzel H (1986) Deutsch Apoth Zt 126:1.494–1.497Google Scholar

bh

  1. 1.
    Moore ML (1951) Glycerophosphoric Acid. In: Kirk RE, Othmer DF (Hrsg.), Encyclopedia of Chemical Technology, Vol. 7, The Interscience Encyclopedia Inc., New York, S. 230Google Scholar
  2. 2.
    Toal JS, Phillips J (1949) J Pharm Pharmacol 1:869–877PubMedCrossRefGoogle Scholar
  3. 3.
    King H, Pyman FL (1914) J Chem Soc 105:1238–1259CrossRefGoogle Scholar
  4. 4.
    NikolicKI, Svecenski NR, Popovic RB (1973) Glas Hem Drus (Beograd) 38:493–497, zit. nach CA 82:64.569tGoogle Scholar
  5. 5.
    Emel’yanenko KV, Dzhan-Temirova TS (1990) Farm Zh (Kiev) 1:60–62, zit. nach CA (1990) 112:185.919dGoogle Scholar
  6. 6.
    Fedorova NN, Reshetnyak VY und Popkov VA (1989) Khim-Farm Zh 23:1396–1400, zit. nach CA (1990) 112: 62.768wGoogle Scholar
  7. 7.
    Madan Bugarin M, Alvarez Sotolongo M, Alvarez Pecoso RM (1986) Rev Cubana Farm 20:77–82, zit. nach CA (1987)106:55.998uGoogle Scholar

WS

  1. 1.
    Haas H, Phosphoroxide, Phosphorsäuren und Phosphate. In: Ull, Bd. 18, S.334Google Scholar
  2. 2.
    Gmelin’s Handbuch der Anorganischen Chemie (1961) Calcium, System-Nr. 28B, S. 1.172fGoogle Scholar
  3. 3.
    Tuckermann MM, Sanchez de Ramos ME (1977) J Pharm Sci 66:1341–1344CrossRefGoogle Scholar

WS

  1. 1.
    Norman AW (1977) Walter de Gruyter, BerlinGoogle Scholar
  2. 2.
    Estler CJ (1983) Lehrbuch der allgemeinen und systematischen Pharmakologie und Toxikologie, Schattauer Verlag, Stuttgart New YorkGoogle Scholar
  3. 3.
    Fülgraff G, Palm D (1989) Pharmakotherapie, Klinische Pharmakologie, Fischer Verlag, Stuttgart New YorkGoogle Scholar
  4. 4.
    Lang F (1980) Klin Wschr 58:985–1.003PubMedCrossRefGoogle Scholar
  5. 5.
    Hauschild F (1960) Pharmakologie und Grundlagen der Toxikologie, Thieme Verlag, LeipzigGoogle Scholar
  6. 6.
    Hornbostel H, Kaufmann W, Siegenthaler W (1977) Innere Medizin in Praxis und Klinik, Thieme Verlag, StuttgartGoogle Scholar
  7. 7.
    Kuemmerle HP, Goossens N (1978) Klinik und Therapie der Nebenwirkungen, Thieme Verlag, StuttgartGoogle Scholar

bh

  1. 1.
    Heubach E, Chloroxide und Chlorsauerstoffsäuren. In: Ull Bd 9, S. 546 ff.Google Scholar

WS

  1. 1.
    Barrette WC, Albrich JM, Hurst JK (1987) Infect Immun 55:2.518–2.525Google Scholar
  2. 2.
    Gottardi W (1988) Hyg Med 13:157–161Google Scholar
  3. 3.
    Dychdala GR (1977) Chlorine and Chlorine Compounds. In: Block SS (Hrsg.) Disinfection, Sterilization, and Preservation, 2. Aufl., Lea & Febiger, Philadelphia, S. 178–179Google Scholar
  4. 4.
    Hugo WB, Russel AD (1980) Pharmaceutical Microbiology, 2. Aufl., Blackwell Scientific Publ, Oxford London Edinburgh Boston Melbourne, S. 173–174Google Scholar
  5. 5.
    Gebhart E (1985) Mutagenität von Antiseptika. In Kramer A, Berencsi G, Weuffen W (Hrsg.) Handbuch der Antiseptik, Bd. I/5, Toxische und allergische Nebenwirkungen von Antiseptika, Volk und Gesundheit, Berlin, S. 279–326Google Scholar
  6. 6.
    Ludewig R, Lohs KH (1988) Akute Vergiftungen, Fischer Verlag, Jena, S. 278–280Google Scholar

ak

  1. 1.
    Harwart A, Kimbel KH, Langecker H, Willenbrink J (1959) Naunyn-Schmiedeberg’s Arch exp Path u Pharmak 237:186–193Google Scholar
  2. 2.
    Ott P, Ott W, Ankel T (1961) Aerztl. Forsch 15,12:563–568Google Scholar
  3. 3.
    Saltzmann GT (1960) Acta Radiol 54,6:417–425Google Scholar
  4. 4.
    Wu SY, Chopra IJ, Solomon DH, Bennett LR (1978) J Clin Endocrinol Metab 46,4:691CrossRefGoogle Scholar

US

  1. 1.
    Gundlach H, Kalk. In: Ull, Bd. 13, S. 497ffGoogle Scholar

WS

  1. 1.
    Dibbern H W, UV-und IR-Spektren der wichtigsten pharmazeutischen Wirkstoffe, Verlag Editio Cantor, AulendorfGoogle Scholar
  2. 2.
    Auterhoff H (1976), Lehrbuch der Pharmazeutischen Chemie, 8. Auflage, Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar

SH

  1. 1.
    Bäßler KH, Grühn E, Loew D, Pietrzik K (1992) Vitamin-Lexikon, Fischer, StuttgartGoogle Scholar
  2. 2.
    Pietrzik K, Hornig D (1980) Int J Vit Nutr Res 50:283–293Google Scholar

KP

  1. 1.
    Dibbern H W (1978) UV-und IR-Spektren der wichtigsten pharmazeutischen Wirkstoffe, Verlag Editio Cantor, AulendorfGoogle Scholar

SH

  1. 1.
    Mar 29, S. 1.080Google Scholar

vB

  1. 1.
    Wirsching F (1985) Calcium Sulfate. In: Gerhartz W (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A4, VCH Verlagsgesellschaft, Weinheim, S.555ffGoogle Scholar

WS

  1. 1.
    Wirsching F (1985) Calcium Sulfate. In: Gerhartz W (Hrsg.) Ulimann’s Encyclopedia of Industrial Chemistry, 5. Aufl, BdA4, VCH Verlagsgesellschaft, Weinheim, S. 555 ffGoogle Scholar

WS

  1. 1.
    Mar 29, S. 933Google Scholar

vB

  1. 1.
    Keberle H (1964) Ann N Y Acad Sci 119:758–768PubMedCrossRefGoogle Scholar
  2. 2.
    Catsch A (1968) Dekorporierung radioaktiver und stabiler Metallionen, Thiemig, München, S. 15–31, 128–155Google Scholar
  3. 3.
    Foreman H (1960) The pharmacology of some useful chelating agents. In: Seven MJ, Johnson LA (Hrsg.) Metal-binding in medicine, JB Lippincott, Philadelphia, S. 82–94Google Scholar
  4. 4.
    Stevens E, Rosoff B, Weiner M, Spencer H (1962) Proc Soc Exper Biol Med 111:235–238Google Scholar
  5. 5.
    Fukuda S, Iida H (1983) Hoken Butsuri 18:37–42CrossRefGoogle Scholar
  6. 6.
    Prosser JS (1978) Brit J Indust Med 35:174–176Google Scholar

Fk

  1. 1.
    Hester BJ (1986) in Berger JG (Edit) Antianxiety Drugs, Wiley, New York 6:51–125Google Scholar
  2. 2.
    Sternbach LH (1978) Progr Drug Res 22:229–266Google Scholar
  3. 3.
    Schütz H (1982) Benzodiazepines I, Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar

  1. 1.
    Mar 29, S.717Google Scholar

vB

  1. 1.
    Rajappa S, Sreenivasan R (1980) Indian J Chem Sect B 19(B) (7):539–541 [CA 94(9): 65553 t]Google Scholar
  2. 2.
    Hoff, Fisher, S Afr P 68 00351, zit. nach CA (1970) 72:90.461qGoogle Scholar
  3. 3.
    Hoff et al (1970) Experientia 26:550PubMedCrossRefGoogle Scholar
  4. 4.
    ShimJSK, Tolan JW, Fink DW (1980) J Pharm Sci 69(3):275–279PubMedCrossRefGoogle Scholar

Rj

  1. 1.
    Friedman PA, Platzer EG (1978) Biochim Biophys Acta 544:605–614PubMedCrossRefGoogle Scholar
  2. 2.
    Ireland CM, Gull K, Gutteridge WE, Pogson CJ (1979) Biochem Pharmacol 28:2680–2682PubMedCrossRefGoogle Scholar
  3. 3.
    Unveröffentlichte Unterlagen der Fa. MSDGoogle Scholar
  4. 4.
    Vandenheuvel WJA, Wolf DE, Arison BH, Buhs RP, Carlin JR, Ellsworth RL, Jacob TA, Koniuszy FR, Smith JL, Trenner NR, Walker RW, Wolf FJ (1978) J Agric Food Chem 26:1357–1364PubMedCrossRefGoogle Scholar
  5. 5.
    Horton FL, Griffiths OV, McMullan MJ (1977) N Z Vet J 25:69–70PubMedCrossRefGoogle Scholar
  6. 6.
    Delatour P, Lorgue G, Lapras M, Deschanel JP (1974) Bull Soc Sci Vét Méd Comp 76:147–154Google Scholar
  7. 7.
    Delatour P, Lorgue G, Lapras M, Richard Y (1976) C R Acad Sc Paris:517–518Google Scholar
  8. 8.
    unveröffentlichte UnterlagenGoogle Scholar
  9. 9.
    Delatour MM, Lorgue G, Courtot D, Lapras M (1975) Bull Soc Sci Vét Méd Comp 77:197–203Google Scholar
  10. 10.
    Drudge JH, Lyons ET, Swerczek TW, Tolliver SC (1983) Am J Vet Res 44:110–114PubMedGoogle Scholar

rk

  1. 1.
    Hana G W, Koch H (1978) Chem Ber Bd 111:2527–2532CrossRefGoogle Scholar
  2. 2.
    Neumüller O (1983) Römpps Chemie-Lexikon Bd. 1, Franckh’sche Verlagshandlung Stuttgart, S. 580Google Scholar
  3. 3.
    Morris DG, Malcolm Murray A (1975) J Chem Soc Perkin Trans II:539–541Google Scholar

  1. 1.
    Mar 29, S. 1.553Google Scholar

vB

  1. 1.
    Ber. Schimmel und Co (1909), Okt. 27Google Scholar
  2. 2.
    Gildemeister, Hoffmann (1963) Bd. IIIc, S.291Google Scholar
  3. 3.
    Banthorpe DV, Whittaker D (1966) Q Rev Chem Soc 20:373CrossRefGoogle Scholar
  4. 4.
    Sörensen TS (1976) Acc Chem Res 9:257CrossRefGoogle Scholar
  5. 5.
    Olah GA (1976) Acc Chem Res 9:41 6. Ana Bd. l3, S.51–59CrossRefGoogle Scholar
  6. 6.
    Ana Bd. l3, S.51–59Google Scholar
  7. 7.
    Alder K (1948) New Methods of Preparative Organic Chemistry, New YorkGoogle Scholar
  8. 8.
    Thomas AF (1973) The Total Synthesis of Natural Products, Bd.2., J Ap Simon (Hrsg.), Wiley-Interscience, New York, S. 149–154Google Scholar
  9. 9.
    Ana, Bd. 13, S.59–61, Academic PressGoogle Scholar
  10. 10.
    Brandstätter M, Frischmann H (1953) Sci Pharm 21:264Google Scholar
  11. 11.
    Guenther Ernest (1961) The essential oils, D. van No-strand Company, Inc., London, Bd. I:397Google Scholar
  12. 12.
    Klemm W, Tilk W, v. Müllenheim S (1928) Z anorg allgem Chemie 176:1–22CrossRefGoogle Scholar
  13. 13.
    Grasselli JC, Ritchey WM (1975) Atlas of Spectral Data and Physical Constants for Organic Compounds, 2. Aufl., Bd. II, CRC Press Inc., Cleveland, OhioGoogle Scholar
  14. 14.
    Swigar AA, Silverstein RM (1981) Monoterpenes-Infrared, Mass, H NMR and 13C NMR spectra and kovats indices, Aldrich Chemical Company, Inc., USAGoogle Scholar
  15. 15.
    Ana, Bd. 13, Academic Press, S.37–44Google Scholar
  16. 16.
    Gehauf B, Goldenson J (1950) Anal Chem 22:498–499CrossRefGoogle Scholar
  17. 17.
    Andrade MA (1984) J Farm (Lisbon) 7:101–107Google Scholar
  18. 18.
    Ray BB, Das Gupta K, Bose H, Das SR (1940) Science and Culture 5:496–497, zit. nach CA (1940) 34:3.989Google Scholar
  19. 19.
    Morani V (1928) Gazz chim ital 58:404–409Google Scholar
  20. 20.
    Little AJ, M’Lean J, Wilson FJ (1940) J Chem Soc:336Google Scholar
  21. 21.
    Lubina B (1974) Pharm Ztg 119:1.444Google Scholar
  22. 22.
    Wagner O (1965) Mitt Geb Lebensmitteluntersuchung Hygiene 56:87Google Scholar
  23. 23.
    Schulek E, Wolstadt R (1936) Z Anal Chem 104:183Google Scholar
  24. 24.
    Hubbert T, Woderer A (1981) DAZ 121:506Google Scholar
  25. 25.
    Marek EM (1978) khim. Farm. Zh. 12:132, zit. nach CA 90:61.307kGoogle Scholar
  26. 26.
    Kaistha KK (1958) Drug Standard 26:183Google Scholar
  27. 27.
    Susser E (1928) Pharm Zentralhalle 69:499–500Google Scholar
  28. 28.
    Ikegami S, Komuta K (1956) Repts Assoc Champhor Ind Eng Japan 21:57Google Scholar
  29. 29.
    Miller JM, Kirchner JG (1953) Anal Chem 25:1.107–1.109Google Scholar
  30. 30.
    Staimer C (1970) Analyse des Medicaments, 4. Aufl., les Presses Universitaires, Liège, S.390Google Scholar
  31. 31.
    Fehr D, Wiegand B (1979) Pharm Ztg 124:1.521Google Scholar
  32. 32.
    Musto JD, Sane JN, Warner VD (1978) J Pharm Sci 67:266PubMedCrossRefGoogle Scholar
  33. 33.
    Cacstighioni A (1936) Ann Chem Applicato 26:53Google Scholar
  34. 34.
    Blake ML, Hopkins LV (1959) Drug Standards 27:39Google Scholar
  35. 35.
    Monies AL, Braun J, Pantolini JC (1954) Anales Direc NaCl Quim (Buenos Aires) 7, No. 13:17Google Scholar
  36. 36.
  37. 37.
  38. 38.
    Nord 63 39. Helv VIIGoogle Scholar

MF

  1. 1.
    Gottlieb R (1923) Die Camphergruppe. In: Heffter (Hrsg.) Hdbch exp Pharmakol 1, Springer, Berlin, S. 1147–1198Google Scholar
  2. 2.
    Treibs W (Hrsg.) (1956) Die ätherischen Öle, 4. Aufl., Academie-Verlag, BerlinGoogle Scholar
  3. 3.
    Mar 29, S. 1552Google Scholar
  4. 4.
    Müller A (1951) Die physiologischen und pharmakologischen Wirkungen der ätherischen Öle, Riechstoffe und verwandten Produkte, 2. Aufl, Hüthig, HeidelbergGoogle Scholar
  5. 5.
    Lendle L, Weigmann R (1955) Pharmakologie. In: Meyer H (Hrsg.) Zahn-Mund-Kieferheilkunde II, Urban & Schwarzenberg, München Berlin, S. 30–32Google Scholar
  6. 6.
    Swinyard EA (1965) Locally acting drugs. In: Goodman LS, Gilman A (Eds.) The pharmacological basis of therapeutics, 3rd ed., Macmillan, New York, p. 982–983Google Scholar
  7. 7.
    Skoglund RR, Ware LL jr, Schanberger JE (1977) Clin Pediatr 16:901CrossRefGoogle Scholar
  8. 8.
    Gossweiler B (1982) Schweiz Rundsch Med 71:1Google Scholar
  9. 9.
    Committee on Drugs (1978) Pediatrics 62:404–406Google Scholar
  10. 10.
    Groot AC de, Nater JP (1988) Dermatological drugs and cosmetics. In: Dukes MNG (Ed.) Meyler’s side effects of drugs, Elsevier, Amsterdam, p. 300Google Scholar
  11. 11.
    Paterson JW (1988) Antiallergic drugs and antitussives. In: Dukes MNG (Ed.) Meyler’s side effects of drugs, Elsevier, Amsterdam, p. 330Google Scholar

Gs

  1. 1.
    Gildemeister, Hoffmann (1963) Bd. IIIc:291Google Scholar
  2. 2.
    Hoffmann W, Janitschke L, Fleig H (1982) in Ullmann, 4. Aufl., Bd. 22, S. 545Google Scholar
  3. 3.
    Robert C Weast (1978–1979) Handbook of Chemistry and Physics, 59th ed., CRC Press Inc., FloridaGoogle Scholar
  4. 4.
    Florey K (1984) Analytical Profiles of Drug Substances, Vol. 13:32, Academic PressGoogle Scholar
  5. 5.
    Umney JC (1916) Perf. Essent. Oil Record 7:46; CA (1962) 10:1.403Google Scholar
  6. 6.
    BohrischP (1907) Pharm Centrh. 48, 527–531; CA (1907) 1:2.662Google Scholar
  7. 7.
    Andrade MA (1948), J Farm (Lisbon) 7:101–107Google Scholar
  8. 8.
    Heffter, Langgard, Bohrisch (1915) Apoth. Ztg. Pharm Zentralhalle, No. 50, H. Schweizer Apoth Ztg. 53:101–102; CA (1915) 9:1.664Google Scholar
  9. 9.
    Patterson, Blackwood, Steward (1933) J Chem Soc 93Google Scholar
  10. 10.
    Baselli A, Giorn Farm Triesle (1907), Gummi Ztg.,Cell. Suppl. 32:31 (Jan 10), C.A. 2, 1.344 (1908)Google Scholar

MF

  1. 1.
    Mar29,S.1552Google Scholar
  2. 2.
    Buchegger G, Vankov T (1983) Therapiewoche 33:4811–4812Google Scholar
  3. 3.
    Gibson DE, Moore GP, Pfaff JA (1989) Am J Emerg Med 7:41–43PubMedCrossRefGoogle Scholar
  4. 4.
    Siegel E, Wason S (1986) Pediatr Clin North Amer 33:357–379Google Scholar

BJ

  1. 1.
    Beil Erg. Werk 3, Bd. 9, S.3876Google Scholar
  2. 2.
    Komppa G (1909) Liebigs Ann.Chem. 370:225Google Scholar
  3. 3.
    Neumüller O (1983) Römpps Chemie-Lexikon Bd. 1:581 Franckh’sche Verlagshandlung, StuttgartGoogle Scholar
  4. 4.

  1. 1.
    Dielmetti P (1952) Farm Sci Pec (Pavia) 7:625–638Google Scholar
  2. 2.
    Edwards BK, Goldberg AA, Wragg AH (1960) J Pharm Pharmacol 12:179–186PubMedCrossRefGoogle Scholar
  3. 3.
    BAZ vom 11. August 1989Google Scholar
  4. 4.
    Helwig B, Helwig H (1980) Moderne Arzneimittel, 5. Aufl., Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  5. 5.
    Mar 28, S. 1060Google Scholar
  6. 6.
    Auclair JM, Anton JP, Bellocq J, Zylberberg B (1970) Rev Fr Gynecol Obstet 65:523–528PubMedGoogle Scholar
  7. 7.
    Windholz M, Budavari S, Stroumtsos LY, Fertig MN (Hrsg.) (1976) The Merck Index-An enzyclopedia of chemicals and drugs, 9. Aufl., Merck & Company, Railway, NJ, USA, S. 1739Google Scholar

KC

  1. 1.
    Mar 29, S. 420Google Scholar

vB

  1. 1.
    Kagawa CM, Bouska DJ, Anderson ML (1964) Proc Soc Exp Biol (NY) 115:837–840Google Scholar
  2. 2.
    Weiner IM (1990) Drugs affecting renal function and electrolyte metabolism. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (Hrsg.) Goodman and Gilmans The Pharmacological Basis of Therapeutics, S.707–731Google Scholar
  3. 3.
    Karim A, Zagarella J, Hutsel TC, Dooley M (1976) Clin Pharmacol Ther 19:159–182Google Scholar
  4. 4.
    Abshagen U, Besenfelder E, Endele R, Koch K, Neubert B (1979) Eur J Clin Pharmacol 25:449–453Google Scholar
  5. 5.
    Krause W, Karras J, Seifert W (1983) Eur J Clin Pharmacol 25:449–453PubMedCrossRefGoogle Scholar
  6. 6.
    Horisberger JD, Giebisch G (1987) Renal Physiol 10:187–192Google Scholar
  7. 7.
    Stier CT Jr, Itskovitz HD (1986) Annu Rev Pharmacol Toxicol 26:101–116PubMedCrossRefGoogle Scholar
  8. 8.
    Osswald H (1978) Med Klin 73:84–88PubMedGoogle Scholar
  9. 9.
    Sadée W, Dagcioglu M, Schröder R (1973) J Pharm Exp Ther 185:686–695Google Scholar
  10. 10.
    Oppermann JA, Piper Ch, Gardiner P (1988) In: Mutschier E (Hrsg.) Therapie mit Aldosteronantagonisten, Urban & Schwarzenberg, München, S.3–9Google Scholar

  1. 1.
    Kagawa CM, Bouska DJ, Anderson ML (1964) Proc Soc Exp Biol (NY) 115:837–840Google Scholar
  2. 2.
    Weiner IM (1990) Drugs affecting renal function and electrolyte metabolism. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (Hrsg.) Goodman and Gilmans The Pharmacological Basis of Therapeutics, S. 707–731Google Scholar
  3. 3.
    Karim A, Zagarella J, Hutsel TC, Dooley M (1976) Clin Pharmacol Ther 19:159–182Google Scholar
  4. 4.
    Abshagen U, Besenfelder E, Endele R, Koch K, Neubert B (1979) Eur J Clin Pharmacol 25:449–453Google Scholar
  5. 5.
    Krause W, Karras J, Seifert W (1983) Eur J Clin Pharmacol 25:449–453PubMedCrossRefGoogle Scholar
  6. 6.
    Horisberger JD, Giebisch G (1987) Renal Physiol 10:187–192Google Scholar
  7. 7.
    Stier CT Jr, Itskovitz HD (1986) Annu Rev Pharmacol Toxicol 26:101–116PubMedCrossRefGoogle Scholar
  8. 8.
    Osswald H (1978) Med Klin 73:84–88PubMedGoogle Scholar
  9. 9.
    Sadée W, Dagcioglu M, Schröder R (1973) J Pharm Exp Ther 185:686–695Google Scholar
  10. 10.
    Oppermann JA, Piper Ch, Gardiner P (1988) In: Mutschier E (Hrsg.) Therapie mit Aldosteronantagonisten, Urban & Schwarzenberg, München, S.3–9Google Scholar

  1. 1.
    Mar 29, S. 1554Google Scholar
  2. 2.
    Gloor M (1982) Pharmakologie dermatologischer Externa, Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar

Gs

  1. 1.
    Masuda K, Yamada T (1976) Biochim Biophys Acta 435:333–339PubMedCrossRefGoogle Scholar
  2. 2.
    Clini V, Grassi C (1970) Antibiot Chemother 16:20–26PubMedGoogle Scholar
  3. 3.
    Burjanova B, Dornetzhuber V (1975) Z Erkr Atmungsorgane 142:68–77PubMedGoogle Scholar
  4. 4.
    McClatchy JK, Kanes W, Davidson PT, Moulding TS (1977) Tubercle 58:29–34PubMedCrossRefGoogle Scholar
  5. 5.
    Tsukamura M (1969) Am Rev Respir Dis 99:780–782PubMedGoogle Scholar
  6. 6.
    Algeorge G, Petre A (1970) Antibiot Chemother 16:32–35PubMedGoogle Scholar
  7. 7.
    Bycroft BW, Croft LR, Johnson AW, Webb T (1972) J Chem Soc Perkin 6:820–827CrossRefGoogle Scholar
  8. 8.
    Sutton WB, Gordon RS, Wick WE, Stanfield L (1966) Ann NY Sci 135:947–959CrossRefGoogle Scholar
  9. 9.
    Kropp R, Ducker I, Jungbluth H (1971) Pneumonologie 144:312–314PubMedCrossRefGoogle Scholar
  10. 10.
    Black HR, Griffith RS, Peabody AM (1966) Ann NY Acad Sci 135:974–982PubMedCrossRefGoogle Scholar
  11. 11.
    König K, Gundlach G, May P, Jochum K (1969) Urologe 8:20–25PubMedGoogle Scholar
  12. 12.
    Jungbluth H (1973) Prax Pneumol 27:175–182PubMedGoogle Scholar
  13. 13.
    Tsukamura M (1972) Tubercle 53:47–52PubMedCrossRefGoogle Scholar
  14. 14.
    Ritter W (1973) Prax Pneumol 27:139–145PubMedGoogle Scholar
  15. 15.
    Lehmann CR, Garrett LE, Winn RE, Springberg PD, Vicks S, Porter DK, Pierson WP, Wolny JD, Brier GL, Black HR (1988) Am Rev Respir Dis 138:1.312–1.313CrossRefGoogle Scholar
  16. 16.
    Radenbach KL (1968) Scand J Respir Dis Suppl 65:195–206PubMedGoogle Scholar
  17. 17.
    Hellstrom PE, Repo UK (1969) Scand J Respir Dis Suppl 69:69–74PubMedGoogle Scholar
  18. 18.
    Orlowski EH (1969) Prax Pneumol 23:178–184PubMedGoogle Scholar
  19. 19.
    Ware M, Heinivaara O, Elo R, Tala E (1969) Scand J Respir Dis Suppl 69:59–63PubMedGoogle Scholar
  20. 20.
    Radenbach KL (1985) Prax Klin Pneumol 39:43–49PubMedGoogle Scholar
  21. 21.
    Mühlberger F (1973) Schweiz Med Wochenschr 103:126–131PubMedGoogle Scholar
  22. 22.
    Mootz W (1972) Z Laryngol Rhinol Otol 51:199–202PubMedGoogle Scholar
  23. 23.
    Kass I (1965) Tubercle 46:166–177PubMedCrossRefGoogle Scholar
  24. 24.
    Garfield JW, Jones JM, Cohen NL, Daly JF, McClement JH (1966) Ann NY Acad Sci 135:1.039–1.046CrossRefGoogle Scholar
  25. 25.
    Hesling CM (1969) Tubercle 50 Suppl:39–41PubMedGoogle Scholar
  26. 26.
    Miller JD, Popplewell AG, Landwehr A, Greene ME (1966) Ann NY Acad Sci 135:1.047–1.056CrossRefGoogle Scholar
  27. 27.
    Rempt E (1981) Z Erkr Atmungsorgane 156(l):64–67PubMedGoogle Scholar
  28. 28.
    Kropp R, Jungbluth H, Radenbach KL (1970) Antibiot Chemother 16:59–68PubMedGoogle Scholar
  29. 29.
    Kropp R (1971) Pneumonologie 145:384–385PubMedCrossRefGoogle Scholar
  30. 30.
    Yue WY, Cohen SS (1966) Dis Chest 49:549–551PubMedCrossRefGoogle Scholar
  31. 31.
    Radenbach KL (1969) Scand J Respir Dis Suppl 69:43–53PubMedGoogle Scholar
  32. 32.
    Darr M, Hamburger S, Eilerbeck E (1982) South Med J 75:627–628PubMedCrossRefGoogle Scholar
  33. 33.
    Davis RR, Brummett RE, Bendrick TW, Hirnes DL (1982) Acta Otolaryngol Stockh 93:211–217PubMedCrossRefGoogle Scholar

Mw

  1. 1.
    Jentsch X, Kubelka W, Rock H (1969) Sci Pharm 37:153–162Google Scholar
  2. 2.
    Spezifikation Capsaicin Merck Nr. ZL-0402573Google Scholar
  3. 3.
    Spezifikation Capsaicine natural E DenkGoogle Scholar
  4. 4.
    Jurenitsch J, Kubelka W, Jentsch X (1978) Sci Pharm 46:305–318Google Scholar
  5. 5.
    Müller-Stock A, Joshi RK, Büchi H(1973) Pharm Acta Helv 40:504–516Google Scholar
  6. 6.
    Glasl H, Ihrig M (1984) Pharmaz Ztg 129:609–612Google Scholar
  7. 7.
    Sticher O, Soldati F, Joshi RK (1978) J Chromatogr 166:221–231CrossRefGoogle Scholar
  8. 8.
    Jurenitsch J, Bingler E, Becker H, Kubelka W (1979) Planta Med 36:54–60PubMedCrossRefGoogle Scholar

Ne

  1. 1.
    Szolcsanyi J (1977) J Physiol (Paris) 73:251–259Google Scholar
  2. 2.
    Carpenter SE, Lynn B (1981) Brit J Pharmacol 73:755–758CrossRefGoogle Scholar
  3. 3.
    Jancso G (1960) Bull Mill Fillimore Hosp 7:53–77Google Scholar
  4. 4.
    Toth-Kasa I, Jancso G, Bognar A, Husz S, Obal F (1986) Int J Clin Pharmacol Res 6:163–169PubMedGoogle Scholar
  5. 5.
    Jancso G, Kiraly E, Jancso-Gabor A (1980) Naunyn-Schmiedeberg’s Arch Pharmacol 313:91–94CrossRefGoogle Scholar
  6. 6.
    Lynn B, Pini A (1985) J Physiol (Lond) 362:115–124Google Scholar
  7. 7.
    Jancso G, Ferencsik M, Such G, Kiraly E, Nagy A, Bugdoso M (1985) Morphological Effects of Capsaicin and its Analogues in Newborn and Adult Mammals. In: Hakanson R, Sundler F (Hrsg.) Tachykinin Antagonists, Elsevier, Amsterdam, S. 35–44Google Scholar
  8. 8.
    Lynn B, Pini A, Baranowski R (1987) Injury of Somatosensory Afferents by Capsaicin: Selectivity and Failure to Regenerate. In: Publos LM, Sessle BJ (Hrsg.) Effects of Injury on Trigeminal and Spinal Somatosensory Systems, Liss, New York S. 115–124Google Scholar
  9. 9.
    Bernstein JE, Bickers DR, Dahl MV, Roshal JY (1987) J Amer Acad Dermatol 17:93–96CrossRefGoogle Scholar
  10. 10.
    Gamse R (1982) Naunyn Schmiedeberg’s Arch Pharmacol 320:205–216CrossRefGoogle Scholar
  11. 11.
    Molnar J (1965) Arzneim Forsch 15:718–726Google Scholar
  12. 12.
    Anonymus (1986) Nutr Rev 44:20–22Google Scholar
  13. 13.
    Weinberg RB (1981) New Engl J Med 305:1020PubMedGoogle Scholar
  14. 14.
    Voge TP (1982) New Engl J Med 306:178Google Scholar
  15. 15.
    Winograd HL (1977) Clin Pediatr 16:884–887CrossRefGoogle Scholar
  16. 16.
    Tominack RL, Spyker DA (1987) Clin Toxicol 25:591–601CrossRefGoogle Scholar

Gs

  1. 1.
    Lee TY, Notari RE (1987) Pharm Res 4:98–103PubMedCrossRefGoogle Scholar
  2. 2.
    Timmins P, Jackson IM, Wang YCJ (1982) Int J Pharm 11:329–336CrossRefGoogle Scholar
  3. 3.
    TaketomoCK, Chu SA, Cheng MH, Corpuz R (1990) Am J Hosp Pharm 47:1799–1801PubMedGoogle Scholar
  4. 4.
    Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar
  5. 5.
    Mills T, Roberson JC (1987) Instrumental Data for Drug Analysis, 2.Aufl., Bd. 1, Elsevier Science Publishing Co., New York Amsterdam LondonGoogle Scholar
  6. 6.
    Perlman S, Kirschbaum J (1981) Chromatogr 206:311–317CrossRefGoogle Scholar
  7. 7.
    Jain R, Jain CL (1991) Indian Drugs 28:380–382Google Scholar

LA

  1. 1.
    Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN (1982) sClin Pharmacol Ther 31:452–458PubMedCrossRefGoogle Scholar
  2. 2.
    Müller H-M, Overlack A, Heck I, Kollocj R, Stumpfe KO (1985) J Hypertension3 (Suppl2):135–136Google Scholar
  3. 3.
    Davidson D, Stalcup SA, Mellins RB (1981) Pediatrics 15:658–674Google Scholar
  4. 4.
    Heald AF, Ita CE (1977) Pharmacologist 19:129–143Google Scholar
  5. 5.
    Kripalani KJ, McKinstry DN, Singhvi SM, Willard DA, Vukovich RA (1989) Clin Pharmacol Ther 27:636–641CrossRefGoogle Scholar
  6. 6.
    Devlin RG,Fleiss PM (1981) J Clin Pharmacol 21:110–113PubMedCrossRefGoogle Scholar
  7. 7.
    Duchin KL, McKinstry DN, Cohen AL, Midalof BH (1988) Clin Pharmacokin 14:241–259CrossRefGoogle Scholar
  8. 8.
    Drummer OH, Jarrott B, Louis WJ (1984b) J Chromatography 305:83–93Google Scholar
  9. 9.
    Brogden RN, Todd PA, Sorkin EM (1988) Drugs 36:540–600PubMedCrossRefGoogle Scholar
  10. 10.
    Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH (1986) N Engl J Med 314:1.657–1.664CrossRefGoogle Scholar
  11. 11.
    Pollare T, Lithell H, Berne C (1989) N Engl J Med 321:868–873PubMedCrossRefGoogle Scholar
  12. 12.
    Packer M, Medina N, Yushak M (1986) Am J Cardiol 57:1.323–1.327Google Scholar
  13. 13.
    Ferguson RK, Brunner HR, Turini GA, Gavres H (1977) Lancet 1:775–778PubMedCrossRefGoogle Scholar
  14. 14.
    Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ (1984) Kidney Int 25:942–947PubMedCrossRefGoogle Scholar
  15. 15.
    Mann J, Ritz E (1988) Theapiewoche 38:1.883–1.890Google Scholar

MJ

  1. 1.
    Clarke CGC (Hrsg.) (1969/1975) Isolation and Identification of Drugs, Pharmaceutical Press, LondonGoogle Scholar
  2. 2.
    Geigy JR Schweiz. Pat. 240, 160 (1.5.1946); CA (1949) 43:6656hGoogle Scholar

PA

  1. 1.
    Mar 29, S. 529Google Scholar

vB

  1. 1.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs. Pharmaceutical Press, LondonGoogle Scholar

PA

  1. 1.
    Tilford CH, van Campen MG, Shelton RS (1947) J Am chern Soc 69:2902CrossRefGoogle Scholar
  2. 2.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, LondonGoogle Scholar
  3. 3.
    Eckert T (1955) Dtsch Apoth Ztg 95:646–647Google Scholar

PA

  1. 1.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 230; s.a. (1977) Drugs Fut 2:715Google Scholar
  2. 2.
    Reimann E (1992) unveröffentlichte ErgebnisseGoogle Scholar
  3. 3.
    Recanatini M (1992) J Pharm Pharmacol 44:68PubMedCrossRefGoogle Scholar
  4. 4.
    Mohamed ME, Tawakkol MS, Aboul-Enein HY (1982) Spectr Letters 15:609; CA (1983) 98:40.667cCrossRefGoogle Scholar
  5. 5.
    Abdel-Hamid ME, Bedair M, Korany A (1985) Pharmazie 40:494PubMedGoogle Scholar
  6. 6.
    Schütz H, Meister T (1990) Arzneim Forsch 40:651Google Scholar
  7. 7.
    Haagsma N, Bathelt ER, Engelsma JW (1988) J Chromatogr 436:73PubMedCrossRefGoogle Scholar
  8. 8.
    Mohamed ME, Tawakkol MS, Abuol-Enein HY (1982) Pharmazie 37:670PubMedGoogle Scholar

RE

  1. 1.
    Bartsch W, Sponer G, Dietmann K (1980) Pharmakologie des Beta-Rezeptorenblockers Carazolol. -Befunde vergleichender tierexperimenteller Untersuchungen an pharmakologischen und pathophysiologischen Modellen. In: Palm D, Rudolph W (Hrsg.) Symposium über den Beta-Rezeptorenblocker Carazolol, Exerpta Medica, S. 44–61Google Scholar
  2. 2.
    Abshagen U, von Möllendorff E (1980) Pharmakokinetik oder Wirkungskinetik von Carazolol? Therapierelevante Daten. In: Palm D, Rudolph W (Hrsg.) Symposium über den Beta-Rezeptorenblocker Carazolol, Excerpta Medica, S. 80–92Google Scholar

PH

  1. 1.
    Rudolph M, Steinhart H, Helpap B (1988) Carbohydr Res 176:155PubMedCrossRefGoogle Scholar
  2. 2.
    Buergisser E, Lefkowitz RJ, DeLean A (1981) Mol Pharmacol (19)3:509, zit. nach CA (1981) 95:143.760vGoogle Scholar

RE

  1. 1.
    Rudolph M, Steinhart H, Helpap B (1988) Carbohydr Res 176:155PubMedCrossRefGoogle Scholar

RE

  1. 1.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 230Google Scholar
  2. 2.
    Zoelss G, Pfarrhofer G (Lentia GmbH), Ger Offen DE 3.544.172, 19.6.1987; CA (1987) 107:242.599xGoogle Scholar
  3. 3.
    Reimann E (1992) unveröffentlichte ErgebnisseGoogle Scholar
  4. 4.
    Buergisser E, Lefkowitz RJ, DeLean A (1981) Mol Pharmacol 19(3):509Google Scholar

RE

  1. 1.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar
  2. 2.
    Doulakas J (1975) Pharm Acta Helv 50:447–450PubMedGoogle Scholar
  3. 3.
    Hanna GM, Lau-Cam CA (1988) Drug Dev Ind Pharm 14:43–51CrossRefGoogle Scholar
  4. 4.
    Lundgren P (1969) Acta Pharm Suecica 6:299–312Google Scholar

LA

  1. 9.
    Metys J, Metysova J, Wagner N, Söndorf N, Herz H (1969) Arzneim Forsch 19:432–433Google Scholar
  2. 10.
    Ruiz RS, Rhem MN, Prager TC (1989) Am J Ophthalm 107:7–10Google Scholar
  3. 11.
    Methfessel HD, Methfessel G (1978) Zbl Gynäkol 00:1310–1319Google Scholar
  4. 12.
    Lamb K, Bradahaw CM, Szabadi E (1983) Eur J Clin Pharmacol 24:55–62PubMedCrossRefGoogle Scholar

GA

  1. 1.
    Kojima K, Sakai K (1978) THL 39:3743–3746Google Scholar
  2. 2.
    Morton DRJr, Brokaw FC (1979) J Org Chem-44:2880–2887CrossRefGoogle Scholar

FA

  1. 1.
    Kraitmair H (1932) Naunyn-Schmiedebergs’s Arch Pharmacol 164:346–356CrossRefGoogle Scholar
  2. 2.
    Rubinstein R, Nissenkorn I, Cohen S (1986) Eur J Pharmacol 123:145–153PubMedCrossRefGoogle Scholar
  3. 3.
    Helund B, Lorentz M, Reintam ACH, Sydbom A (1988) Pharmacol Toxicol 62:12–16CrossRefGoogle Scholar
  4. 4.
    Brazil OV, Fontane MD, Pavani NJP (1983) Eur J Pharmacol 86:199–205CrossRefGoogle Scholar
  5. 5.
    Mizushima A, Uchida S, Matsumozo K, Osugi T, Kagiya , Zhou XM, Higuchi H, Yoshida A (1985) Eur J Pharmacol 119:177–182PubMedCrossRefGoogle Scholar
  6. 6.
    Schümann HJ, Wagner J, Springer W (1977) Arzneim Forsch 27:2353–2357Google Scholar
  7. 7.
    Bolton TB, Clapp LH (1986) Br J Pharmac 87:713–723Google Scholar
  8. 8.
    Alfödi P, Obál F, Toth E, Hideg J (1986) Eur J Pharmacol 123:312–327Google Scholar
  9. 1.
    Gryglewski RJ (1987) In: Gryglewski RJ, Stock G (Hrsg.) Prostacyclin and its stable analogue iloprost, Springer, Berlin Heidelberg New York, S. 3–15CrossRefGoogle Scholar
  10. 2.
    Skuballa W, Radüchel B, Vorbrüggen H (1987) In: Gryglewski RJ, Stock G (Hrsg.) Prostacyclin and its stable analogue iloprost, Springer, Berlin Heidelberg New York, S. 17–24CrossRefGoogle Scholar

AB

  1. 1.
    US Pat. 2948718 (Schindler W, (Geigy) ert. 9.8.1960), zit. nach CA 55:1671c (1961); DDR Pat. 133052 (Müller R, Anm. 8.9.77), zit. nach CA (1979) 91:74489sGoogle Scholar
  2. 2.
    Clarke CGC (Hrsg.) (1969/1975) Isolation and Identification of Drugs, Pharmaceutical Press, LondonGoogle Scholar
  3. 3.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, LondonGoogle Scholar
  4. 4.
    Aboul-Enein HA, Al-Badr AA (1980) Carbamazepin. In: Florey K (Hrsg.) Analytical Profiles of Drug Substances 9, S.87ffGoogle Scholar

PA

  1. 1.
    Zona C, Tancredi V, Palma E, Pirrone GC, Avoli M (1990) Can J Physiol Pharmacol 68:545–547PubMedCrossRefGoogle Scholar
  2. 2.
    Zimanyi I, Weiss SRB, Lajtha A, Post RM, Reith MAE (1989) Eur J Pharmacol 167:419–422PubMedCrossRefGoogle Scholar
  3. 3.
    Weiss SRB, Post RM, Szele F, Woodward R, Nierenberg J (1989) Brain Res 497:72–79PubMedCrossRefGoogle Scholar
  4. 4.
    Schwarz J, Grigat G (1989) Epilepsia 30:286–294PubMedCrossRefGoogle Scholar
  5. 5.
    Mimaki T, Susuki Y, Tagawa T (1988) Shinkei Kenkyu no Shinpo 33:899–908Google Scholar
  6. 6.
    Nagaki S, Kato N, Minatogawa Y, Higuchi T (1990) Life Sci 46:1687–1695CrossRefGoogle Scholar
  7. 7.
    Searles CD, Slesinger PA, Singer HS (1988) Neurochem Res 13:1007–1013PubMedCrossRefGoogle Scholar
  8. 8.
    Cologero AE, Kamilaris TC, Bernadini R, Johnson EO, Chrousos GP, George P, Gold PW (1990) J Pharmacol Exper Ther 253:729–737Google Scholar
  9. 9.
    Elphick M, Taghavi Z, Powell T, Godfrey PP (1990) Psychopharmacol 100:522–529CrossRefGoogle Scholar
  10. 10.
    Elphick M (1989) Psychopharmacol 99:532–536CrossRefGoogle Scholar
  11. 11.
    Julien RM, Hollister RP (1975) Carbamazepin: Mechanisms of actions. In: Penry JK, Daly DD (Eds.) Advances in Neurology, Vol. 11, Raven Press, New York, S. 263–277Google Scholar
  12. 12.
    Fukuda A, Akagi K, Masuda Y, Zushi K (1989) Igaku to Seibutsugaku 118:85–87Google Scholar
  13. 13.
    Bertilsson L (1978) Clin Pharmacokinet 3:128–143PubMedCrossRefGoogle Scholar
  14. 14.
    MacKichan JJ, Kutt H (1981) Carbamazepine. Therapeutic use and serum concentration monitoring. In: Taylor WJ, Finn AL (Eds.) Individualizing drug therapy. Practical applications of drug monitoring, Gross Townsend Frank Inc., New York, S.2–25Google Scholar
  15. 15.
    Wada JA, Troupin AS, Friel P, Remick R, Leal K, Pearmain J (1978) Epilepsia 19:251–255PubMedCrossRefGoogle Scholar
  16. 16.
    Neuvonen PJ (1985) J Clin Pharmacol Therap Toxicol 23:226–232Google Scholar
  17. 17.
    Miyamoto K, Seino M, Ikeda Y (1975) Consecutive determination of the levels of twelve antiepileptic drugs in blood and cerebrospinal fluid. In: Schneider H, Janz D, Gardner-Thorpe C, Meinardi H, Sherwin AL (Eds.) Clinical pharmacology of antiepileptic drugs, Springer, New York Heidelberg Berlin, S. 323–330CrossRefGoogle Scholar
  18. 18.
    Friis ML, Christiansen J, Hvidberg EF (1978) Eur J Clin Pharmacol 14:47–51PubMedCrossRefGoogle Scholar
  19. 19.
    Froescher W, Eichelbaum M, Niesen M, Dietrich K, Rausch P (1984) Ther Drug Monitor 6:288–291CrossRefGoogle Scholar
  20. 20.
    Bertilsson L, Tomson T (1986) Clin Pharmacokinet 11:177–198PubMedCrossRefGoogle Scholar
  21. 21.
    Patsalos PN, Krishna S, Elyas AA, Lascelles PT (1987) Hum Toxicol 6:241–244PubMedCrossRefGoogle Scholar
  22. 22.
    Theisohn M, Sigmund M, Heimann G, Roth B (1978) Nebenwirkungshäufigkeit und Blutspiegelverlauf von Carbamazepin und seinem antikonvulsiv wirkenden Metaboliten Carb-10,ll-epoxyd nach einmaliger und nach chronischer Gabe beim Gesunden. In: Doose H, Groß-Seelbeck G (Hrsg.) Epilepsie 1978, Epilepsiebedingte Hirnschäden-Psychogene Anfälle-Audiovisuelle Anfallsanalyse. Jahrestagung der Deutschen Sektion der Internationalen Liga gegen Epilepsie, Kiel, Mai 1978, Thieme, Stuttgart, S. 197–205Google Scholar
  23. 23.
    Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, Tyrer JH (1977) Eur J Clin Pharmacol 12:451–456PubMedCrossRefGoogle Scholar
  24. 24.
    Eichelbaum M, Köthe KW, Hoffman F, Unruh GE von (1979) Clin Pharmacol Ther 26:366–371PubMedGoogle Scholar
  25. 25.
    Schain RJ, Ward JW, Guthrie D 81977) Neurology 27:476–480PubMedCrossRefGoogle Scholar
  26. 26.
    Rey E, D’Athis R, Lauture D de, Dulac D, Aicardi J, Olive G (1979) Int J Clin Pharmacol Biopharm 17:90–96PubMedGoogle Scholar
  27. 27.
    Yerby MS, Friel PN, Miller DQ (1985) Ther Drug Monitor 7:269–273CrossRefGoogle Scholar
  28. 28.
    Kuhntz W, Steldinger R, Nau H (1984) Develop Pharmacol Ther 7:61–72Google Scholar
  29. 29.
    Armijo JA, Herranz JL, Arteaga R, Valiente R (1986) Clin Pharmacokinet 11:323–335PubMedCrossRefGoogle Scholar
  30. 30.
    Takahashi R, Hagiwara M, Watabe M, Amanabu I, Kan R, Takahashi Y, Kumashiro H (1989) Neurosci 15:311–317Google Scholar
  31. 31.
    Covington TR, Di Palma JR, Hussar DA, Lasagna L, Tatro DS, Whitsett TL (1988) Carbamazepine. In: Kastrup EK, Olin BR, Connell SI (Eds.) Drug facts and comparisons, Lippincott, St. Louis, S. 1.164–1.168Google Scholar
  32. 32.
    Armijo JA, Herranz JL, Valiente E, Arteaga R (1989) Rev Farmacol Clin Exp 6:83–88Google Scholar
  33. 33.
    Livingstone S, Pauli LL, Berman W (1974) Dis Nerv Syst 35:103–107Google Scholar
  34. 34.
    Donaldson GWK, Graham JG (1965) Brit J Clin Prac 19:699–701Google Scholar
  35. 35.
    Zucker P, Daum F, Cohen M (1977) J Pediatr 91:667–668PubMedCrossRefGoogle Scholar
  36. 36.
    Riley RJ, Kitteringham NR, Park BK (1989) Br J Clin Pharmacol 28:482–487PubMedCrossRefGoogle Scholar
  37. 37.
    Shear NH, Spielberg SP (1988) J Clin Invest 82:1826–1832PubMedCrossRefGoogle Scholar
  38. 38.
    Lee IG, Whang KT (1989) K’at’ollik Taehak Uihakpou Nonmunjip 42:695–703Google Scholar
  39. 39.
    Hoenack D, Loescher W (1989) Neuropharmacol 28:599–610CrossRefGoogle Scholar
  40. 40.
    Janz D (1978) Dtsch Med Wschr 103:485–487PubMedCrossRefGoogle Scholar
  41. 41.
    Mendez-Alvarez E, Soto-Otero R, Galan-Valiente J, Sierra-Marcuno G (1990) Epilepsia 31:202–210PubMedCrossRefGoogle Scholar
  42. 42.
    Chang SL, Levy RH (1985) J Pharmacokin Biopharm 13:563–566Google Scholar
  43. 43.
    Hagiwara M, Takahashi R, Watabe M, Amanuma I, Kan R, Takahashi Y, Kumashiro H (1988) Neurosci 15:303–309Google Scholar
  44. 44.
    Panesar SK, Orr JM, Farrell K, Burton RW, Kassahun K, Abbott FS (1989) Br J Clin Pharmac 27:323–328CrossRefGoogle Scholar
  45. 45.
    Kondo T, Otani K, Hirano T, Kaneko S, Fukushima Y (1990) Br J Clin Pharmac 20:116–119CrossRefGoogle Scholar
  46. 46.
    Turner P, Renton KW (1989) Can J Physiol Pharmacol 67:582–586PubMedCrossRefGoogle Scholar
  47. 47.
    Durelli L, Massazza U, Cavallo R (1989) Med Toxicol Adv Drug Exper 4:95–107CrossRefGoogle Scholar
  48. 48.
    Ellenhorn MJ, Barceloux DG (1988) Medical toxicology. Diagnosis and treatment of human poisoning, Elsevier Science Publ, New York, p. 231–240Google Scholar
  49. 49.
    Troupin AS, Ojemann LM (1975) Epilepsia 16:753–758PubMedCrossRefGoogle Scholar
  50. 50.
    Howard RS, Trend PStJ, Townsend HRA (1990) Hum Exper Toxicol 9:313–315CrossRefGoogle Scholar
  51. 51.
    Bock E, Keller F, Heitz J, Heinemeyer G (1989) Int J Clin Pharmacol Ther Toxicol 27:P490–P492Google Scholar
  52. 52.
    Lee CC, Marbury TC (1984) Clin Pharmacokinet 9:42–66PubMedCrossRefGoogle Scholar

Hg

  1. 1.
    Drebinger K, Dittberner H (1986) Fortschr Med 104:480–482PubMedGoogle Scholar
  2. 2.
    Frankl R (1953) Muench Med Wochenschr 95: 512–513Google Scholar
  3. 3.
    Assmann G (1954) Ther Gegenw Heft 2:51–52Google Scholar
  4. 4.
    Loew D, Schuster O, Biehl J (1990) Rheuma 10:259–262Google Scholar
  5. 5.
    Nizankowska E, Szczeklik A (1979) Dtsch Med Wochenschr 104:1.388–1.389Google Scholar
  6. 6.
    Loew D, Schuster O, Rau G, Biehl J (1991) Intern J Clin Pharmacol Therap Toxicol 29:124–129Google Scholar

Me

  1. 1.
    Haynes HL, Lambrech JA, Moorefield HH (1957) Contrib Boyce Thompson Inst 18:507–513, zit. nach CA (1958) 52:642cGoogle Scholar
  2. 2.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar
  3. 3.
    Kuhr RJ, Dorough HW (1976) Carbamate Insecticides: Chemistry, Biochemistry and Toxicology, CRC Press, ClevelandGoogle Scholar

MA

  1. 1.
    Kuhr RJ, Dorough HW (1975) Carbamate Insecticides: Chemistry, Biochemistry, and Toxicology, CRC Press, Cleveland, OhioGoogle Scholar
  2. 2.
    Casida JE (1963) Ann Rev Entomol 8:39CrossRefGoogle Scholar
  3. 3.
    Carpenter CP, Weil CS, Palm PE, Woodside MD, Nair JH, Smyth HF (1961) -methyl carbamate (Sevin insecticide), Agr Food Chem 9:30–39CrossRefGoogle Scholar
  4. 4.
    Miller E, Earl FL, Michel TC, Vanloom EJ (1973) Lab Anim Drug Test Sympos Inst Comm Lab Animals:45–51Google Scholar
  5. 5.
    Smalley HE (1970) JAVMA 156 (3):339–344PubMedGoogle Scholar
  6. 6.
    Pohlmann R, Werner E, Eschke R (1976) MH Vetmed 31Google Scholar
  7. 7.
    Georghiou GP (1972) Am J Trop Med Hyg 21:797PubMedGoogle Scholar
  8. 8.
    Wharton RH, Roulston WJ (1970) Ann Rev Entomol 15:381CrossRefGoogle Scholar
  9. 9.
    Iwata T, Hama H (1972) J Econ Entomol 65:643PubMedGoogle Scholar
  10. 10.
    Brown AW, Pal R (1971) Insect Resistance in Arthropods, 2. Aufl., World Health Organization, GenfGoogle Scholar
  11. 11.
    Boch J, Supperer R (1983) Veterinärmedizinische Parasitologic, Parey, Berlin HamburgGoogle Scholar
  12. 12.
    Mathysse JG, Vreden G van, Purnasiri A, Jones CJ, Netherton HR, McClain DS (1975) Search Agriculture, Entomology 4:11–42Google Scholar
  13. 13.
    Rust MK, Reierson DA (1988) J Econ Entomol 81:236–240PubMedGoogle Scholar
  14. 14.
    El-Gazzar LM, Patterson RS, Koehler PG (1988) Florida Entomologist 71:359–363CrossRefGoogle Scholar
  15. 15.
    Houston JB, Upshall DG, Bridges JW (1974) Xenobiotica 5:637–648CrossRefGoogle Scholar
  16. 16.
    Lechner DW, Abdel-Rahman MS (1986) J Toxicol Environ Health 18:241–256CrossRefGoogle Scholar
  17. 17.
    Cambon C, Fernandez Y, Falzon M, Mitjavila S (1981) Toxicology 22:45–51PubMedCrossRefGoogle Scholar
  18. 18.
    Knaak JB, Yee K, Ackermann CR, Zweig G, Fry DM, Wilson BW (1984) Toxicol Appl Pharmacol 76:252–263PubMedCrossRefGoogle Scholar
  19. 19.
    Price GM, Kuhr RJ (1969) -methylcarbamate) by fat body of the blowfly larva Calliphora erythrocephala, Biochem J 112:133PubMedGoogle Scholar
  20. 20.
    Golbs S, Kühnert M, Leue F (1975) Proc Europ Soc Toxicol 16:54–59Google Scholar
  21. 21.
    Knaak JB, Tallant MJ, Bartley WJ, Sullivan LJ (1965) J Agric Food Chem 13:537–543CrossRefGoogle Scholar
  22. 22.
    Collins THX, Hansen WH, Keeler HV (1971) Toxicol Appl Pharmacol 19:202–216PubMedCrossRefGoogle Scholar
  23. 23.
    Smalley HE, Curtis JM, Earl FL (1968) Toxicol Appl Pharmacol 13:392–403PubMedCrossRefGoogle Scholar
  24. 24.
    Vashakidze VI (1967) Soobshch Aked Nauk Gruz SSR 48:219–224; Abstracted in Chem Abstr 68:287500X (1968)Google Scholar
  25. 25.
    Shtenberg AI, Rybakova MN (1968) Food Cosmet Toxicol 6:461–467PubMedCrossRefGoogle Scholar
  26. 26.
    Dikshith TSS, Gupta PK, Gaur JS, Datta KK, Mathur AK(1976) Environm Res 12:161–170CrossRefGoogle Scholar
  27. 27.
    Orlova NV, Zhalbe EP (1969) Vop Pitan 27:49–55 (in russian); Abstract in Chem Abstr 70:46402 F (1969)Google Scholar
  28. 28.
    Branch RA, Jacqz E (1986) Am J Med 80:741–745PubMedCrossRefGoogle Scholar

rk

  1. 1.
    Lippincott JB, Company (Hrsg.) (1989) Drugs facts and comparisons, St. Louis (USA), S. 1.606–1.607Google Scholar
  2. 2.
    Nauck EG (Hrsg.) (1956) Lehrbuch der Tropenkrankheiten, Georg Thieme Verlag, Stuttgart, S. 126–131Google Scholar
  3. 3.
    Ali BH, Abdelaziz M (1982) Vet Record 110:506CrossRefGoogle Scholar
  4. 4.
    Knock F, Galt R, Oester Y, Sylvester R, Rebechini-Zasadny H (1979) Oncology 36:197–201PubMedCrossRefGoogle Scholar
  5. 5.
    McDougald LR (1979) Poultry Science 58:76–80PubMedCrossRefGoogle Scholar
  6. 6.
    Sullivan TW, Al-Timini AA (1972) Poultry Science 51:1.498–1.501Google Scholar
  7. 7.
    Worden AN, Wood EC (1973) J Sci Fd Agric 24:35–41CrossRefGoogle Scholar
  8. 8.
    Amlacher E (1986) Taschenbuch der Fischkrankheiten, 5. Aufl., Gustav Fischer Verlag, S. 278–280Google Scholar
  9. 9.
    Hwang SW, Schanker LS (1973) Xenobiotica 3:351–355PubMedCrossRefGoogle Scholar
  10. 10.
    Schmid A (1983) Dtsch tierärztl Woschenschr. 90:10–13Google Scholar
  11. 11.
    Oser BL, Morgareidge K, Weinberg MS, Oser M (1966) Toxic Appl Pharmacol 9:528–535CrossRefGoogle Scholar
  12. 12.
    Kourounakis P, Szabo S, Villeneuve C, Gagnon M (1973) J Europ de Toxicologic 6:232–236Google Scholar
  13. 13.
    NN (1983) Fed Regist 48:2.757–2.758Google Scholar

HA

  1. 1.
    Lentenneur J (1984) Sem Hop Paris 60:1.089–1.091Google Scholar
  2. 2.
    Arramon JY, Cayla F, Clement A (1987) Semaine des Hopitaux 63:1.297–1.300Google Scholar
  3. 3.
    Mlczoch F, Treml E (1950) Wiener Klin Wochenschr 62:974–977Google Scholar
  4. 4.
    Bonard EC, Barbezat G (1955) Schweiz Med Wochenschr 85:684–685PubMedGoogle Scholar
  5. 5.
    Lowenthal W, Borzelleca JF, Corder CD JR (1970) J Pharm Sci 59:1.353–1.355CrossRefGoogle Scholar
  6. 6.
    Borg KO, Ekenved G, Elofsson R (1975) Acta Pharma Suec 12:491–198Google Scholar
  7. 7.
    Pesendorfer FX (1979) Dr MED 3:32–33Google Scholar
  8. 8.
    Gruber K (1962) Wiener Med Wochenschr 112:507–509Google Scholar

Me

  1. 1.
    Balenovic K, Bregant N, Perina I (1973) Synth. 172Google Scholar
  2. 2.
    Beaudet C, Debot H, Lambot H, Toussaint J (1951) Experientia 7:291–294PubMedCrossRefGoogle Scholar
  3. 3.
    Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identifikation of Drugs, The Pharmaceutical Press, LondonGoogle Scholar
  4. 4.
    Powell WS, Heacock RA, Smith DG, Mclness AG (1973) Can J Chem 51:776–779Google Scholar

VF

  1. 1.
    McLean WM, Campolongo JT (1973) Can J Surg 16:333–334PubMedGoogle Scholar
  2. 2.
    Fleshier B (1976) Surg Clin North Am 56:1.375–1.386Google Scholar
  3. 3.
    Nakada T, Sasagawa I, Koike H, Furuta H, Katayama T, Ota K, Chikenji M, Matushita T, Saito H (1989) Int Urol Nephrol 21:3–8PubMedCrossRefGoogle Scholar
  4. 4.
    Kangasniemi P (1979) Headache 19:219–222PubMedCrossRefGoogle Scholar
  5. 5.
    Mar 29, S. 1132–1133Google Scholar

EH

  1. 1.
    Neu HC (1982) Med Clin North Amer 66:61–77Google Scholar
  2. 2.
    Meyers BR, Hirschmann SZ, Strougo L, Srulevitch E (1980) Antimicrob Agents Chemother 17:608–611PubMedCrossRefGoogle Scholar
  3. 3.
    Tan JS, Salstrom SJ (1977) Antimicrob Agents Chemother 11:698–700PubMedCrossRefGoogle Scholar
  4. 4.
    Neu HC, Garvey GJ (1975) Antimicrob Agents Chemother 8:457–162PubMedCrossRefGoogle Scholar
  5. 5.
    Monographie Carbenicillin, BAz Nr.148 vom 10.8.1991, Jg. 43, 5.355Google Scholar
  6. 6.
    Pancoast SJ, Neu HC (1978) Clin Pharmacol Ther 24:108–116PubMedGoogle Scholar
  7. 7.
    Anonymous author (1987) Microbiology and pharmacokinetics of parenteral penicillins, Hoffmann-LaRoche Inc. (Hrsg.), S. 1–34Google Scholar
  8. 8.
    Barza M, Weinstein L (1976) Clin Pharmacokinet 1:297–308PubMedCrossRefGoogle Scholar
  9. 9.
    Cole M, Kenig MD, Hewitt VA (1973) Antimicrob Agents Chemother 3:463–468PubMedCrossRefGoogle Scholar

cw

  1. 1.
    Bronch SK, Casy AS, Ominde EMA (1987) J Pharm Biomed Anal 5:73–103CrossRefGoogle Scholar
  2. 2.
    Martin JL, Duncombe RE, Shaw WHC (1975) Analyst 100:243–248PubMedCrossRefGoogle Scholar
  3. 3.
    Heinisch G, Gerold W (1981) Pharmazie 36:347–348Google Scholar
  4. 4.
    Hendrickx S, Roets E, Hoomgartens J, Vanderhaeghe H (1984) J Chromatogr 291:211–218CrossRefGoogle Scholar
  5. 5.
    Agarwal Sp, Nwaiwu J (1985) J Chromatogr 323:424–429CrossRefGoogle Scholar
  6. 6.
    Bundgaard H, Ilver K (1972) J Pharm Pharmac 24:790–794CrossRefGoogle Scholar
  7. 7.
    Pospisilava B, Simkova M, Kubes J (1986) Pharmazie 41:705–708Google Scholar
  8. 8.
    Hagel RB, Waysek EH, Cort WM (1979) Antimicrob Agents Chemother 16:372–377PubMedCrossRefGoogle Scholar
  9. 9.
    Rizk M, Walash MI, Abou-Ouf AA, Belal F (1981) Anal Lett 14:1407–1417CrossRefGoogle Scholar
  10. 10.
    Haginaka J, Wakai J (1985) Analyst: 110:1185–1188PubMedCrossRefGoogle Scholar
  11. 11.
    Levy RL (1980) J Chromatogr 192:467–473CrossRefGoogle Scholar
  12. 12.
    Chan CY, Chan K, French GL (1986) J Antimicrob Chemother 18:537–545PubMedCrossRefGoogle Scholar

HO

  1. 1.
    Goodier TEW (1968) Histopathology of gastric ulcers treated with carbenoxolone. In: Robson JM, Sullivan FM (Hrsg.) A Symposium on Carbenoxolone Sodium, Butterworths, London, S. 111–126Google Scholar
  2. 2.
    Bickel M, Kaufmann GL (1981) Gastroenterology 80:770–775PubMedGoogle Scholar
  3. 3.
    Henmann FD /1970) Gut 11:344–351CrossRefGoogle Scholar
  4. 4.
    Thompson MR, Elder JB, Rhodes CR, Gillespie IE (1975) Effects of local irrigations of carbenoxolone on back-diffusion of hygrogen ions in pouch dogs. In: Avery Jones F, Parke DV (Hrsg.) Fourth Symposium on Carbenoxolone, Butterworth, London, S.25–40Google Scholar
  5. 5.
    Lipkin M (1970) Carbenoxolone sodium and the rate of extrusion of gastric epithelial cells. In: Baron JH, Sullivan FM (Hrsg.) Carbenoxolone Sodium, Butter-worths, London, S. 11–15Google Scholar
  6. 6.
    Peskar BM (1980) Scand J Gastroentol (Suppl.) 65:109–112Google Scholar
  7. 7.
    Hausmann W, Tarnoky AL (1966) Br J Pharmacol 26:412–420Google Scholar
  8. 8.
    Turpie AGG, Thompson TJ (1965) Gut 6:591–594PubMedCrossRefGoogle Scholar
  9. 9.
    Werning C, Bayer JM, Fischer N, Schweikert HU, Siegenthaler W (1972) Dtsch Med Wochenschr 97:91–92PubMedGoogle Scholar
  10. 10.
    Parke DV (1983) Acta Gastroent Belg 46:437–447PubMedGoogle Scholar
  11. 11.
    Baron JH, Gribble RJN, Rodes C, Wright PA (1975) Factors affecting the absorption of carbenoxolone in patients with peptic ulcers. In: Avery Jones F, Parke DV (Hrsg.) Fourth Symposium on Carbenoxolone, Butterworths, London, S. 115–124Google Scholar
  12. 12.
    Downer HD, Galloway RW, Horwick L, Parke DV (1970) J Pharma Pharmacol 22:479–187CrossRefGoogle Scholar
  13. 13.
    Parke DV (1972) The biochemistry od carbenoxolone. In: Avery Jones F, Sullivan FM (Hrsg.) Carbenoxolone in Gastroenterology, Butterworths, London, S.19–32Google Scholar
  14. 14.
    Pinder RM, Brogden RN, Swyer PR, Speight TM, Spencer R, Avery GS (1976) Drugs 11:245–307PubMedCrossRefGoogle Scholar
  15. 15.
    Mitchell ABS (1971) Postgrad Med J 47:807–813PubMedCrossRefGoogle Scholar
  16. 16.
    Barnes PC, Leonard JHC (1971) Postgrad Med J 47:813–814PubMedCrossRefGoogle Scholar
  17. 17.
    Baron JH, Elkeles RS, Lloyd-Mostyn RH, Watt I (1970) The effect of carbenoxolone sodium on carbohydrate metabolism. In: Baron JH, Sullivan FM (Hrsg.) Carbenoxolone Sodium, Butterworths, London, S. 19–30Google Scholar
  18. 18.
    Wynn V (1968) Metabolic effects of carbenoxolon sodium administration in man. In: Robson JM, Sullivan FM (Hrsg.) A Symposium on Carbenoxolone Sodium, Butterworths, London, S. 173–194Google Scholar
  19. 19.
    Laubenthal F (1972) Dtsch Med Wochenschr 97:1.351–1.354CrossRefGoogle Scholar
  20. 20.
    Doll R, Langman MJS, Shawdon HH (1968) Gut 9:42–45PubMedCrossRefGoogle Scholar
  21. 21.
    Reed PJ, Lewis SJ, Vincent A, Brown DJ, Holdstock RJN, Gribble RE, Murgatroyd J, Baron H (1980) Scand J Gastroentol (Suppl.) 65:93–96Google Scholar
  22. 22.
    Edmonds CJ (1977) Br Med J 1:775PubMedCrossRefGoogle Scholar
  23. 23.
    Sullivan FM (1972) Pharmacology and toxicology of carbenoxolone. In: Avery Jones F, Sullivan FM (Hrsg.) Carbenoxolone in Gastroenterology, Butterworths, London, S. 3–18Google Scholar

Wb

  1. 1.
    Liu KC, Lee LC, Kong WY, Hsieh TT (1978) T’ai-wan Yao Hsueh Tsa Chih 30:69–72; CA (1980) 92:181422 gGoogle Scholar
  2. 2.
    Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, 2nd Ed., The Pharmaceutical Press, LondonGoogle Scholar
  3. 3.
    Rhodes C, Wright PA (1974) J Pharm Pharmac 26:894–898CrossRefGoogle Scholar
  4. 4.
    Peskar BM, Wachter W, Heissmeyer H, Gerok W (1977) Verh Dtsch Ges Inn Med 83:1717–1719PubMedGoogle Scholar
  5. 5.
    Kracmar J, Kracmarova J, Bokovikova TN, Ciciro VE (1990) Cesk Farm 39:385–393; CA (1991) 114:171408rGoogle Scholar

LA

  1. 1.
    Cedarbaum JM, Schleifer LS (1990) Drugs for Parkinson’s disease, spasticity, and acute muscle spasms. In: Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.) Goodman and Gilman’s the pharmacological basis of therapeutics. 8. Aufl., Pergamon Press, New York, S.463–484Google Scholar
  2. 2.
    Mar 29, S. 1014Google Scholar
  3. 3.
    Männistro PT, Kaakkola S (1990) Pharmacol Toxicol 66:317–323CrossRefGoogle Scholar
  4. 4.
    Quinn NP (1984) Drugs 28:236–262PubMedCrossRefGoogle Scholar
  5. 5.
    Cedarbaum JM (1987) Clin Pharmacokinet 13:141–178PubMedCrossRefGoogle Scholar
  6. 6.
    Kuruma I, Bartholini G, Tissot R, Pletscher A (1972) J Pharm Pharmacol 29:288–294Google Scholar
  7. 7.
    Müller EE, Locatelli V, Cella S, Penalva A, Novelli A, CocchiD(1983) Drugs 25:399–432PubMedCrossRefGoogle Scholar

NB

  1. 1.
    Karady S, Ly MG, Pines SH, Sletzinger M (1971), J Org Chem 36:1946–1949CrossRefGoogle Scholar
  2. 2.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs. Pharmaceutical Press, LondonGoogle Scholar

PA

  1. 1.
    Jansson R, Dahlberg PA, Lindström B (1983) Int J Clin Pharmacol Ther Toxicol 21:505–510PubMedGoogle Scholar
  2. 2.
    Lazarus JH, Marchant B, Alexander WD, Clark DH (1975) Clin Endocrinol 4:609–615CrossRefGoogle Scholar
  3. 3.
    Marchant B, Alexander WD, Lazarus JH, Lees J, Clark DH (1972) J Clin Endocrinol Metab 34:847–851PubMedCrossRefGoogle Scholar
  4. 4.
    Melander A, Haiengren B, Rosendal-Helgesen S, Sjoberg AK, Wahlin-Boll E (1980) Eur J Clin Pharmacol 17:295–299PubMedCrossRefGoogle Scholar

WI

  1. 1.
    Sperber N, Papa D, Schwenk E, Sherlock M (1949) J Am Chem Soc 71:887PubMedCrossRefGoogle Scholar
  2. 2.
    McNeil Laboratories (1962) BP 905993, zit. nach CA (1963) 58:5643Google Scholar
  3. 3.
    Jap Pat 90515636 (1963), zit. nach CA (1964) 60:4115hGoogle Scholar

MP

  1. 1.
    Mar 29, Carbinoxamine, S. 447Google Scholar
  2. 2.
    Connell JT, Gold AJ, Zola EM, Paule CL (1984) Drug Intell Clin Pharm 18:244–247PubMedGoogle Scholar
  3. 3.
    Seppala T, Nuotto E, Korttila K (1981) Br J Clin Pharmacol 12:179–188PubMedGoogle Scholar

EH

  1. 1.
    Mc Neil Laboratories (1962) BP 905993, zit. nach CA (1963) 58:5643Google Scholar
  2. 2.
    Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, AulendorfGoogle Scholar
  3. 3.
    Clarke’s Isolation and Identification of Drugs (1986) The Pharmaceutical Press, LondonGoogle Scholar

MP

  1. 1.
    BAz, Nr. 190a vom 10.10.1985Google Scholar

GS

  1. 1.
    BAz, Nr. 190a vom 10.10.1985Google Scholar

GS

  1. 1.
    Goodman L, Ross LO, Baker (1958) J Org Chem 23:1251–1257CrossRefGoogle Scholar
  2. 2.
    Armstrong Md, Lewis JD (1951) J Org Chem 16:749–753CrossRefGoogle Scholar
  3. 3.
    Schioberl A, Wagner A (1956) Z physiolog Chemie 304:97CrossRefGoogle Scholar
  4. 4.
    Aylward M (1973) Curr med Res Opinion 1:219–222CrossRefGoogle Scholar

JM/Mo

  1. 1.
    Puchelle E, Aug F, Polu JM (1978) Eur J Clin Pharmacol 14:177–184PubMedCrossRefGoogle Scholar
  2. 2.
    Quevauviller A, Farcet S, Vu-Ngoc-Huyen (1976) Therapiewoche 26:8.244–8.255Google Scholar
  3. 3.
    Degand P (1973) Bull Physio-path Respir 9:462–464Google Scholar
  4. 4.
    Köhler D, Siebold A, Daikeler G, Matthys H (1982) Atemw-Lungenkrkh 8:201–205Google Scholar
  5. 5.
    Matthys H, Vastag E, Daikeler G, Köhler D (1984) In: Nolte D, Krejci G (Hrsg.) Methylxanthine bei obstruktiven Atemwegserkrankungen, Dustri, München Deisenhofen, S. 111–121Google Scholar
  6. 6.
    Aylward M (1973) Curr Med Res Opinion 1:219–227CrossRefGoogle Scholar
  7. 7.
    Miskovits G, Szüle P, Appel J, Meszaros M (1984) Med Prax 79:88–92,157–162Google Scholar
  8. 8.
    Edwards GF, Steel AE, Scott JK, Jordan JW (1976) Chest 70:506–513PubMedCrossRefGoogle Scholar
  9. 9.
    Thompson ML, Pavia D, Jones CJ, Mcquiston TAC (1975) Thorax 30:669–673CrossRefGoogle Scholar
  10. 10.
    Muittari A, Linnoila M (1977) Curr Ther Res 22:246–252Google Scholar
  11. 11.
    Lutz D, Gielsdorf W, Rasper J, Jaeger H, Altring M, Eisler G, Niebch G (1985) Arzneim Forsch/Drug Res 35:163–166Google Scholar
  12. 12.
    Braga PC, Borsa M, Angelis L De et al. (1982) Clin Therap 4:480–488Google Scholar
  13. 13.
    Servin A, Garcet S, Vu-Ngoc-Huyen, Cohen Y (1976) J Pharmacol 7:275–286Google Scholar
  14. 14.
    Mitchell SC, Waring RH, Haley CS, Idle JR, Smith RL (1984) Br J Clin Pharmac 18:507–521CrossRefGoogle Scholar
  15. 15.
    Mitchell SC, Waring RH, Idle JR, Smith RL (1981) IRCS Clin Pharmacol Ther 9:1.028–1.029Google Scholar

sz

  1. 1.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 336Google Scholar
  2. 2.
    Amos K, Auterhoff H (1979) Dtsch Apoth Ztg 119:1440Google Scholar
  3. 3.
    Auterhoff H, Kovar KA (1985) Identifizierung von Arzneistoffen, 5. Aufl., Wissenschaftl. Verlagsges. mbH Stuttgart, S. 151; 304 (Abb.)Google Scholar
  4. 4.
    Masumarra G, Scarlata G, Cirma G (1985) J Chromatogr 350:151CrossRefGoogle Scholar
  5. 5.
    DaldrupT, Susanto F, Michalke P (1981) Fresenius Z Anal Chem 308:413CrossRefGoogle Scholar
  6. 6.
    Taha AM, Abd El-Kader MA (1979) J Chromatogr 177:405PubMedCrossRefGoogle Scholar
  7. 7.
    Pawelczyk E, Plotkowiak Z, Dubrownik-Cira D (1975) Acta Pol Pharm 32:325; CA (1976) 84:79657kPubMedGoogle Scholar

RE

  1. 1.
    Fiedler VB, Kettenbach B, Nitz RE (1980) Arch Int Pharmacodyn Ther 244:292–308PubMedGoogle Scholar
  2. 2.
    Fiedler VB, Gobel H, Nitz RE (1985) J Cardiovasc Pharmacol 7:964–970PubMedCrossRefGoogle Scholar
  3. 3.
    Fiedler VB, Kettenbach B, Gobel H, Nitz RE (1985) J Cardiovasc Pharmacol 7:964–970PubMedCrossRefGoogle Scholar
  4. 4.
    Salzmann G (1977) Fortschr Med 7:453–456Google Scholar
  5. 5.
    Heinroth I, Forster W (1984) Prostaglandins Leukot Med 14:13–14PubMedCrossRefGoogle Scholar
  6. 6.
    Ostrowski J (1979) Arzneim Forsch 29:889–894Google Scholar
  7. 7.
    Djonlagic H, Diederich KW (1981) Arzneim Forsch 31:2.072–2.074Google Scholar
  8. 8.
    Franchi F, Padelatti L, Brat A, Michelucci A, Pala AM (1981) Int J Clin Pharmacol Ther Toxicol 19:256–259PubMedGoogle Scholar
  9. 9.
    Bell H, Azarnoff DL, Dunn M (1968) Clin Pharmacol Ther 9:40–44PubMedGoogle Scholar
  10. 10.
    Kipsidzen N, Kikava GM (1976) Arzneim Forsch 26:882–885Google Scholar
  11. 11.
    Opherk D, Schuler G, Waas W, Dietz R, Kubler W (1990) Eur Heart J 11:342–347PubMedGoogle Scholar
  12. 12.
    Martin YC, Wiegand RG (1970) J Pharm Sci 59:1.313–1.318CrossRefGoogle Scholar
  13. 13.
    Fiedler VB (1981) Am J Cardiol 48:978–980PubMedCrossRefGoogle Scholar

  1. 1.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 337Google Scholar
  2. 2.
    Breazu D, Kovendi A, Fey L, Deesy A, Laurentiu O, Dasoveanu M, Gavris M, Szabo S (1977) Rom 62.587; CA (1980) 92:22.383dGoogle Scholar
  3. 3.
    Auterhoff H, Kovar KA (1985) Identifizierung von Arzneistoffen, 5. Aufl., Wissenschaftliche Verlagsgesellschaft, S. 151Google Scholar
  4. 4.
    Amos K, Auterhoff H (1979) Dtsch Apoth Ztg 119: 1440Google Scholar
  5. 5.
    Klarwein M, Nitz RE (1965) Arzn Forschg 15:555Google Scholar
  6. 6.
    Kracmar J, Kracmarova J (1989) Pharmazie 44:199Google Scholar
  7. 7.
    NakamachiH,Yamaoka T, Wada Y, Miyata K (1982) Chem Pharm Bull 30:3685CrossRefGoogle Scholar
  8. 8.
    Yamaoka T, Nakamachi H, Miyata K (1982) Chem Pharm Bull 30:3695PubMedCrossRefGoogle Scholar
  9. 9.
    Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Ed. Cantor, Aulendorf, Nr. 1402Google Scholar
  10. 10.
    Sulkowska J, Maciejczyk D, Zaleska E (1990) Pharmazie 45:630Google Scholar
  11. 11.
    Zommer-Urbanska S, Urbanska J (1985) Pharmazie 40:419PubMedGoogle Scholar

RE

  1. 1.
    DAB 9-Kommentar, Bd. 3, S.2818.; Bd.4, S.3.641Google Scholar
  2. 2.
    Handbook of Pharmaceutical Exipients (1986) APhA Washington, USA, S. 41/42Google Scholar

BK

  1. 1.
    BAz, Nr. 109a vom 16.06.1987Google Scholar

GS

  1. 1.
    Hopkins SJ (1983) Pro 8:489–491Google Scholar
  2. 2.
    Koen S, Pashankov P (1987) Izv.-Durzh. Inst. Kontrol Lek. Sredstva 20:22–29, zit. nach CA (1988) 108:119083tGoogle Scholar

WM

  1. 1.
    Micetich KC, Barnes D, Erickson LC (1985) Cancer Res 45:4.043–4.047Google Scholar
  2. 2.
    Gaver RC, Swigor JE, George AM, Haynes UJ, Deeb G (1986) Proc AACR 27:288, Abstr. 1.141Google Scholar
  3. 3.
    Knox RJ, Friedlos F, Lydall DA; Roberts JJ (1986) Cancer Res 46:1.972–1.979Google Scholar
  4. 4.
    Roberts JJ, Knox RJ, Friedlos F, Lydall DA (1986) DNA as a target for the cytotoxic and antitumor action of platinum coordination complexes: Comparative in vitro and in vivo studies of cisplatin and carboplatin. In: McBrien DHC, Slater TF (Hrsg.) Biochemical Mechanisms of Platinum Antitumor Drugs. IRL Press, Oxford Washington DC, S. 29–56Google Scholar
  5. 5.
    Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD (1988) J Clin Pharmacol 28:208–215PubMedCrossRefGoogle Scholar
  6. 6.
    Canetta R, Goodlow J, Smaldane L, Bragman K, Rozencweig M (1990) Pharmacologic characteristics of carboplatin. Clinical expericence. In: Carboplatin (JM 8). Current perspectives and future directions, WB Saunders, Philadelphia, S. 19–39Google Scholar
  7. 7.
    Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Cancer Treat Rev 12 Suppl A:ll 1–124Google Scholar
  8. 8.
    Van Hennik MB, vander Vijgh WJF, Klein I, Elferink F, Vermorken JB, Winograd B, Pinedo HM (1987) Cancer Res 47:6.290–6.301Google Scholar
  9. 9.
    Siddik ZH, Newell DR, Boxall FE, Harrap KR (1987) Biochem Pharmacol 36:1.925–1.932CrossRefGoogle Scholar
  10. 10.
    Siddik ZH, Jones M, Boxall FE, Harrap KR (1988) Cancer Chemother Pharmacol 21:19–24PubMedCrossRefGoogle Scholar
  11. 11.
    Boven E, vander Vijgh WJF, Nauta MM, Schlüper HMM, Pinedo HM (1985) Cancer Res 45:86–90PubMedGoogle Scholar
  12. 12.
    Litterst CL (1984) Plasma pharmacokinetics, urinary excretion, and tissue distribution of platinum following iv administration of cyclobutane dicarboxylatoplatinum (II) and cis-platinum to rabbits. In: Hacker MP, Douple EB, Krakoff IH (Hrsg.) Platinum Coordination Complexes in Cancer Chemotherapy, Martinus Nijhoff Publishing, Boston The Hague Dordrecht Lancaster, S. 71–81CrossRefGoogle Scholar
  13. 13.
    Siddik ZH, Dible SE, Boxall FE, Harrap KR (1986) Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. In: McBrien DCH, Slater TF (Hrsg.) Biochemical Mechanisms of Platinum Antitumour Drugs, IRL Press, Oxford Washington DC, S. 171–191Google Scholar
  14. 14.
    Vander Vijgh WJF, Lelieveld P, Klein I, Putten LM, Pinedo HM (1983) Proc 13th ICC 17:57–59Google Scholar
  15. 15.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Cancer Res 44:1.693–1.697Google Scholar
  16. 16.
    Thigpen JT, Blessing JA, Vance RB, Lambuth BW (1989) Semin Oncol 16 (4 Suppl 6):58–85PubMedGoogle Scholar
  17. 17.
    Thatcher N, Lind M (1990) Semin Oncol 17:40–48PubMedGoogle Scholar
  18. 18.
    Eisenberger M, Van Echo D, Aisner J (1989) Semin Oncol 16 (2 Suppl 5):34–41PubMedGoogle Scholar
  19. 19.
    Canetta R, Bragman K, Smaldone L, Rozenczweig M (1988) Cancer Treat Rev 15 Suppl B:17–32PubMedCrossRefGoogle Scholar
  20. 20.
    Einhorn LH (1988) Semin Oncol 15 (Suppl 3):9–15PubMedGoogle Scholar
  21. 21.
    Coughlin CT, Richmond RC (1989) Semin Oncol 16 (4 Suppl 6):31–43PubMedGoogle Scholar
  22. 22.
    Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Drugs 37:162–190PubMedCrossRefGoogle Scholar
  23. 23.
    Ozols RF (1989) Semin Oncol 16 (4 Suppl 6):22–30PubMedGoogle Scholar
  24. 24.
    Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C (1986) Otolaryngol Head Neck Surg 94:458–496PubMedGoogle Scholar
  25. 25.
    Rose WC, Schurig JE (1985) Cancer Treat Rev 12 Suppl A:l-19PubMedCrossRefGoogle Scholar
  26. 26.
    Achterrath W, Wilke H, Kroll-von Haeseler (1988) Firmenbroschüre Bristol Arzneimittel, Toxikologie (Ref 56)Google Scholar

Mw

  1. 1.
    Handbook of Pharmaceutical Excipients, APhA Washington, USA, S. 44Google Scholar

BK

  1. 1.
    Handbook of Pharmaceutical Excipients, APhA Washington, USA, S. 45–48Google Scholar

BK

  1. 1.
    Müller E, Pevny I, Metz G (1972) Hautarzt 24:317–319Google Scholar
  2. 2.
    Mar 29, S. 1433Google Scholar
  3. 3.
    Gilman AG, Goodman LS, Rall TW, Murad F (1988) Goodman and Gilman’s The pharmacogical basis of therapeutics, 7. Aufl., Macmillan, New York, S. 951Google Scholar
  4. 4.
    Mar 28, S. 951Google Scholar
  5. 5.
    Wyatt GM, Horn N, Gee JM, Johnson IT (1988) Br J Nutr 60:197–207PubMedCrossRefGoogle Scholar
  6. 6.
    Brooks RR, Pong SF (1981) Biochem Pharmacol 30:589–594PubMedCrossRefGoogle Scholar
  7. 7.
    Eisold H, Arnold M, Graumann W (1969) ZZellforsch 99:336–345CrossRefGoogle Scholar
  8. 8.
    Samandari F (1974) Anat Anz 135:348–356PubMedGoogle Scholar
  9. 9.
    Hamada T, Horiguchi S (1978) Cont Dermat 4:244CrossRefGoogle Scholar
  10. 10.
    Ammon HPT (1981) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 381Google Scholar
  11. 11.
    Kasai M, Kanamitsu M, Katada T, Tokumitsu Y, Itaya K, UiM (1977) Toxicology 8:327–332PubMedCrossRefGoogle Scholar
  12. 12.
    Begin F, Vachon C, Jones MD, Wood PJ, Savoie L (1989) Can J Physiol Pharmacol 67:1265–1271PubMedCrossRefGoogle Scholar
  13. 13.
    Wise A, Mallett AK, Rowland IR (1986) Toxicology 38:241–248PubMedCrossRefGoogle Scholar
  14. 14.
    Johnson IT, Gee JM (1986) Br J Nutr 55:497–505PubMedCrossRefGoogle Scholar
  15. 15.
    Klugmann FB, Decorti G, Mallardi F, Baldini L (1984) Pharmacol Res Comm 16:313–318CrossRefGoogle Scholar
  16. 16.
    Behall KM, Scholfied DJ, LeeK, Powell AS, Moser PB (1987) Am J Clin Nutr 46:307–314PubMedGoogle Scholar
  17. 17.
    Forster H, Hoss I (1977) Z Ernährungswiss 16:140–149PubMedCrossRefGoogle Scholar
  18. 18.
    Bachmann E, Weber E, Post M, Zbinden G (1978) Pharmacology 17:39–49PubMedCrossRefGoogle Scholar

PK

  1. 1.
    Beilstein 3 E I 29, E II 52, E III 125, E IV 117Google Scholar
  2. 2.
    Dibbern HW (1983) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, AulendorfGoogle Scholar
  3. 3.
    Müller RK (1976) Die toxikologisch-chemische Analyse, 1. Aufl., Verlag Chemie, Weinheim, S. 249Google Scholar
  4. 4.
    In: Grasselli JC, Ritchey WM (Hrsg.) (1975) C R C Atlas of Spectral Data and Physical Constants for Organic Compounds, 2. Aufl., Bd. IV, CRC Press, ClevelandGoogle Scholar
  5. 5.
    Kovar KA, Noy M, Pieper R (1982) Dtsch Apoth Ztg 122:3–22Google Scholar

EK

  1. 1.
    Vohland HW, Hadisoemarto S, Wanke B (1976) Arch Toxicol 36:31–42PubMedCrossRefGoogle Scholar
  2. 2.
    Vohland HW, Streichert B (1978) Arch Toxicol 41:69–77PubMedCrossRefGoogle Scholar
  3. 3.
    Zimmermann W, Braun W (1977) Arch Toxicol 38:287–294PubMedCrossRefGoogle Scholar
  4. 4.
    Eichelbaum M, Sonntag B, Unruh G v (1978) Arch Toxicol 41:187–193PubMedCrossRefGoogle Scholar
  5. 5.
    Vohland HW, Hadisoemarto S, Wanke B (1977) Arch Toxicol 37:275–288PubMedCrossRefGoogle Scholar
  6. 6.
    Vohland HW, Schirop T, Barckow D, Kreutz G, Streichert B (1978) Arch Toxicol 40:211–219PubMedCrossRefGoogle Scholar
  7. 7.
    Gruska H, Beyer KH, Grosse G, Wolbergs E (1971) Arch Toxicol 28:149–158CrossRefGoogle Scholar
  8. 8.
    Hampel G, Crome P, Widdop B, Goulding R (1980) Arch Toxicol 45:133–145PubMedCrossRefGoogle Scholar
  9. 9.
    Butte W, Meyer GJ, Vollnberg W (1978) Arch Toxicol 41:61–67PubMedCrossRefGoogle Scholar

Hg

  1. 1.
    Trokhimchuk UV, Alekseev VV (1988) Farm Zh (Kiev) 5:68–69Google Scholar
  2. 2.
    Agarwal SP, Nwaiwu J (1986) J Chromatogr 351:383–387CrossRefGoogle Scholar
  3. 3.
    Zorya BP, Petrenko VV, Kulek IA (1989) Farmatsiya (Moscow) 38:69–71Google Scholar
  4. 4.
    Sofomonova SG, Petrenko VV, Turkevich MM (1978) Farm Zh (Kiev) 5:75–77Google Scholar
  5. 5.
    Gaidukevich AN, Sidom MB (1977) Farm Zh (Kiev) 4:70–73Google Scholar
  6. 6.
    Iskender G, Orak F (1986) Istanbul University Eczacilik Fak. Mecm. 22:9–15Google Scholar
  7. 7.
    El-Gizawy S (1991) Bull Fac Sci, Assitut Univ 20:65–72Google Scholar

As

  1. 1.
    Quattrin N, Jacono G, Brancaccio AG (1957) Minerva med 48:1.449Google Scholar
  2. 2.
    Stowers JM, Mahler RF, Hunter RB (1958) Lancet I:278CrossRefGoogle Scholar
  3. 3.
    Ridolfo AS, Kirtley WR (1956) J Amer med Assoc 160:1.285CrossRefGoogle Scholar
  4. 4.
    Klaus D, Stripecke W (1957) Z ges inn Med 12:289PubMedGoogle Scholar
  5. 5.
    Waldhäusel W (1984) Endokrines Pankreas: Diabetes mellitus. In: Kümmerle HP, Hitzenberger G, Spitzy KH (Hrsg.) Klinische Pharmakologie, ecomed Verlagsgesellschaft Landsberg/Lech, S. 15–28Google Scholar
  6. 6.
    Knick B (1984) Spektrum Antidiabetika, Aesopus Verlag Zug, S. 30–48Google Scholar
  7. 7.
    Stowers JM, Borthwick LJ (1977) Drugs 14:41–56PubMedCrossRefGoogle Scholar
  8. 8.
    International monitoring of adverse reactions to drugs. Report Type A. Carbutamide (1983) WHO Collaborating Centre for international drug monitoring, S.89–99Google Scholar
  9. 9.
    Drury MJ, Wolanczyk WJ (1956) J Irish Med Assoc 39:100–105Google Scholar
  10. 10.
    Camerini-Davalos R, Root HF, Marble A (1957) Diabetes Vol 6:74–77Google Scholar
  11. 11.
    Jackson JE, Dressier R (1981) Drugs 22:211–245, 295–320PubMedCrossRefGoogle Scholar
  12. 12.
    Joiner CL, Lee CT, Duncan GG (1957) Diabetes 6:83–84PubMedGoogle Scholar
  13. 13.
    Dinnendahl V, Fricke U (Hrsg.) (1987) Carbutamid. In: Arzneistoff profile, Govi Verlag FrankfurtGoogle Scholar
  14. 14.
    Hansen JM, Christensen LK (1977) Drugs 13:24–34PubMedCrossRefGoogle Scholar
  15. 15.
    Pogatsa G, Koltai MZ, Balkanyi I, Devai I, Kiss V, Koszeghy A (1988) Acta physiol Hung 71:243PubMedGoogle Scholar
  16. 16.
    Seltzer HS (1981) Adverse drug interactions of clinical importance to diabetics. In: Rifkn H, Raskin P (Hrsg.) Diabetes mellitus Vol.5, R. Brady Co., S.327–334Google Scholar
  17. 17.
    Seltzer HS (1979) Comprehensive Therapy 5:21–29PubMedGoogle Scholar
  18. 18.
    Skillman TG, Feldman JM (1981) Am J Med 70:351–372CrossRefGoogle Scholar
  19. 19.
    Downs GE, Linkewich JA, DiPalma JR (1981) Geriatrics 36:45–48PubMedGoogle Scholar

VE

  1. 1.
    Drug Fut (1976) 1:412Google Scholar
  2. 2.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 245Google Scholar
  3. 3.
    KaiserC, Colella DF, Schwartz MS, Garvey E, Wardell Jr. JR (1974) J Med Chem 17:49CrossRefGoogle Scholar
  4. 4.
    Ravin LJ, Rattie ES, Peterson A, Guttman DE (1978) J Pharm Sci 67:1523PubMedCrossRefGoogle Scholar

RE

  1. 1.
    Mar 29, S. 1.458Google Scholar

vB

  1. 1.
    Ravin LJ, Rattie ES, Peterson A, Guttman DE (1978) J Pharm Sci 67:1523PubMedCrossRefGoogle Scholar
  2. 2.
    Kaiser C, Colella DF, Schwartz MS, Garvey E, Wardell JR Jr. (1974) J Med Chem 17:49PubMedCrossRefGoogle Scholar
  3. 3.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl. Noyes Publications, Park Ridge, New Jersey USA, S. 245Google Scholar

RE

  1. 1.
    Kaiser C, Colella DF, Schwartz MS, Garvey E, Wardell JR Jr. (1974) J Med Chem 17:49PubMedCrossRefGoogle Scholar

RE

  1. 1.
    Kaiser C, Colella DF, Schwartz MS, Garvey E, Wardell JR Jr.(1974) J Med Chem 17:49PubMedCrossRefGoogle Scholar

RE

  1. 1.
    Clayton JP, Cole M, Elson SW, Hardy KD, Mizen LW, Sutherland R (1975) J Med Chem 18:172–177PubMedCrossRefGoogle Scholar
  2. 2.
    Hendrickx S, Roets E, Hoogmartens J, Vanderhaeghe H (1984) J Chromatogr 291:211–218CrossRefGoogle Scholar
  3. 3.
    Agarwal SP, Nwaiwu (1985) J Chromatogr 323:424–429CrossRefGoogle Scholar

HO

  1. 1.
    Mar 29, S. 141Google Scholar

vB

  1. 1.
    Mar 29, S. 717Google Scholar

vB

  1. 1.
    Clayton JP, Cole M, Elson SW, Hardy KD, Mizen LW, Sutherland R (1975) J Med Chem 18:172–177PubMedCrossRefGoogle Scholar
  2. 2.
    Overvlieth, Vos HL, Smits HM (1975) Pharm Weekbl 109:537–542Google Scholar
  3. 3.
    Gerold W, Heinisch G (1981) Pharmazie 36:347–348Google Scholar
  4. 4.
    Park MK, Cho JH, Park YH (1987) Soul Taeh Yak Nonmun 64:67–75, zit. nach CA (1989) lll:102798uGoogle Scholar
  5. 5.
    Pfizer Quality Control Division, Standard Test Procedure, persönl. Mitt.Google Scholar
  6. 6.
    Whittaker JW, Lemke PR (1982) J Pharm Sci 71:334–338PubMedCrossRefGoogle Scholar

HO

  1. 1.
    Monographie: Carindacillin, BAz Br.148 vom 10. August 1991 Jg 43:5.355Google Scholar
  2. 2.
    Anonymer Autor (1979) Carbenicillin, Indanyl Carbenicillin and Carfecillin. In: Kucers A, Bennett NMcK (Hrsg.) The use of antibiotics, 3. Aufl., William Heinemann Medical Books 1st, London, S. 149–169Google Scholar

CW

  1. 1.
    Ebel S (1979) Synthetische Arzneimittel, VCH, Weinheim New York, S. 250Google Scholar
  2. 2.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S.436Google Scholar
  3. 3.
    Turczan J, Kram T (1967) J Pharm Sci 56:1643PubMedCrossRefGoogle Scholar
  4. 4.
    Herstellerangaben Deutsche Robapharm, PfaffenweilerGoogle Scholar

DG

  1. 1.
    Berger FM, Keltzkin M, Ludwig BJ, Margolin S (1960) Ann NY Acad Sci 86:90–107PubMedCrossRefGoogle Scholar
  2. 2.
    Cooper CD, Epstein JH (1959) In: Miller JG (Hrsg.) The pharmacology and clinical usefulness of carisoprodol, Wayne State University press, DetroitGoogle Scholar
  3. 3.
    Baratta RR (1976) Curr Ther Res 20:233–240PubMedGoogle Scholar
  4. 4.
    Gallardo F, Molgo J, Miyazaki C, Rossi E (1975) J Oral Surg 33:655–658PubMedGoogle Scholar
  5. 5.
    Mar 29 Carisoprodol, S. 1.231Google Scholar

EH

  1. 1.
    Johnston TP, McCaleb GS, Montgomery JA (1963) J Med Chem 6:669–681PubMedCrossRefGoogle Scholar

WM

  1. 1.
    Montgomery J, Ruby J, McCaleb GS et al. (1967) J Med Chem 10:688Google Scholar
  2. 2.
    ColvinM,BrundrettRB,Cowens JW et al.(1976) Biochem Pharmacol 25:695PubMedCrossRefGoogle Scholar
  3. 3.
    Bowdon BJ, Grimsley J, Lloyd HH (1974) Cancer Res 34:194PubMedGoogle Scholar
  4. 4.
    Hill DL, Kirk MC, Struck RF (1975) Cancer Res 35:296PubMedGoogle Scholar
  5. 5.
    Levin VA, Stearns J, Byrd A et al. (1979) J Pharmacol Exp Ther 208:1PubMedGoogle Scholar
  6. 6.
    Levin VA, Hoffman W, Weinkam RJ (1978) Cancer Treat Rep 62:1305PubMedGoogle Scholar
  7. 7.
    Falkson G, Falkson HC (1981) Chemother Pharmacol 6:31Google Scholar
  8. 8.
    Moertel C (1978) New Engl J Med 299:1049PubMedCrossRefGoogle Scholar
  9. 9.
    Preusser P, Achterrath W, Wilke H et al. (1988) Cancer Treat Rev 15:257–277PubMedCrossRefGoogle Scholar
  10. 10.
    Green SB, Byar DP, Walker MD et al. (1983) Cancer Treat Rep 67:123Google Scholar
  11. 11.
    Vita VT de, Carbone PP, Owens AH et al. (1965) Cancer Res 25:1876PubMedGoogle Scholar
  12. 12.
    Bailey CC, Marsden HB, Jones PH (1978) Cancer 42:74PubMedCrossRefGoogle Scholar
  13. 13.
    Schacht RG, Baldwin DS (1978) Kidney Int 14:661Google Scholar

OJ

  1. 1.
    Strack E, Müller DM (1970) Hoppe-Seyler’s Physiolog Chem 351(l):95–98CrossRefGoogle Scholar
  2. 2.
    Strack E, Röhnert H, LorenzI (1953) Chem Ber 86:525–529CrossRefGoogle Scholar

Gm

  1. 1.
    Kato G, Hosein EA (1969) Can of Chem 47:1177–1187CrossRefGoogle Scholar
  2. 2.
    Friedmans, Galun AB, Fraenkel G (1957) Arch of Biochem and Biophys 66:10–15CrossRefGoogle Scholar

Gm

  1. 1.
    Voeffray R, Perlberger JC, Tenud L (1987) Helv Chim Acta 70:2058–2064CrossRefGoogle Scholar
  2. 2.
    Eigene MessungenGoogle Scholar
  3. 3.
    Strack E, Lorenz I (1960) Hoppe-Seyler’s Physiol Chem 318:129–137CrossRefGoogle Scholar

Gm

  1. 1.
    Bohles H (1985) Infusionsther Klin Ernähr 12:60–69PubMedGoogle Scholar
  2. 2.
    Mokhova E, Arrigoni-Martelli E, Beilei M, Dedukhova V, Muscatello U, Starhov A, Bobyleva V (1991) FEBS Lett 289:187–189PubMedCrossRefGoogle Scholar
  3. 3.
    Goa KL, Brogden RN (1987) Drugs 34:1–24PubMedCrossRefGoogle Scholar
  4. 4.
    Borum PR (1983) Annu Rev Nutr 3:233–59PubMedCrossRefGoogle Scholar
  5. 5.
    Bahl JJ, Bressler R (1987) Annu Rev Pharmacol Toxicol 27:257–277PubMedCrossRefGoogle Scholar
  6. 6.
    Genger H, Enzelsberger H, Salzer H (1988) Z Geburtshilf Perinatol 192:155–157Google Scholar
  7. 7.
    Emmrich J, Seim H (1985) Folia Haematol 112:373–381Google Scholar
  8. 8.
    Bach AC, Schiradin H, Sihr MO, Storck D (1983) Diabet Metabol 9:121–124Google Scholar
  9. 9.
    Cederblad G (1984) Clin Physiol 4:159–168PubMedCrossRefGoogle Scholar
  10. 10.
    Welling PG, Thomsen JH, Shug AL, Tse FL (1979) Int J Clin Pharmacol Biopharm 17:56–60PubMedGoogle Scholar
  11. 11.
    Anonymous (1987) Lancet II:429–431Google Scholar
  12. 12.
    Bizzi A, Mingardi G, Codegoni AM, Mecca G, Garattini S (1978) Biomedicin 29:183–184Google Scholar
  13. 13.
    Savica V, Bellingheri G, Di Stefano C, Corvaja E, Consolo F, Corsi M, Maccari F, Spagnoli LG, Villachi S, Palmieri G (1983) Nephron 35:232–236PubMedCrossRefGoogle Scholar
  14. 14.
    Chalmers RA, Stacey TE, Tracey BM, de Sousa C, Roe CR, Millington DS, Hoppel CL (1984) J Inherit Metab Dis 7, Suppl2:109–110PubMedGoogle Scholar
  15. 15.
    Roe CR, Millington DS, Maitby DA, Bohan TP, Happel CL (1984) J Clin Invest 73:1.785–1.788CrossRefGoogle Scholar
  16. 16.
    Tao RC, Yoshimura NN (1980) J Parent Ent Nutrit 4:469–486CrossRefGoogle Scholar
  17. 17.
    Bowyer BA, Fleming CR, Ilstrup D, Nelson J, Reek S, Burnes J (1986) Am J Clin Nutr 43:85–91PubMedGoogle Scholar
  18. 18.
    Matsuda I, Ohtani Y, Ninomiya N (1986) J Pediatr 109:131–134PubMedCrossRefGoogle Scholar
  19. 19.
    Anonymous (1987) Med Lett 28:88–89Google Scholar
  20. 20.
    Bazzato G, Coli U, Landini S, Mezzina C, Ciman M (1981) LancetI, 1.209Google Scholar

vB

  1. 1.
    Mar 29, S. 1.257Google Scholar

vB

  1. 1.
    Berger L, Corraz AJ (1974) (Hoffmann-LaRoche, 14.II.74) Ger Offen 2.337.340, zit. nach CA 80:108366Google Scholar
  2. 2.
    Berger L, Cofgen DL, Manchand P, Mandeville WH (1985) (Hoffmann-LaRoche, 14.VIII. 85) Eur Pat App EP 151.423, zit. nach CA 103:215168Google Scholar
  3. 3.
    Kemmerer JM, Rubio FA, McClain RM, Koechlin BA (1979) J Pharm Sci 68:1.274–1.280CrossRefGoogle Scholar

Ub

  1. 1.
    O’Brien WM, Bagby GF (1987) Pharmacotherapy 7:16–24PubMedGoogle Scholar
  2. 2.
    Konturek SJ, Kwiecien N, Obtulowicz W, Kiec-Dembinska A, Polanski M, Kopp B, Sito E, Oleksy J (1982) Hepatogastroenterology 29:267–270PubMedGoogle Scholar
  3. 3.
    Konturek SJ, Kwiecien N, Obtulowicz W, Zmuda A, Polanski M, Kopp B, Sito E, Oleksy J (1983) Hepatogastroenterology 30:261–265PubMedGoogle Scholar
  4. 4.
    Levine RA, Petokas S, Nandi J, Enthoven D (1988) Dig Dis Sci 33:660–666PubMedCrossRefGoogle Scholar
  5. 5.
    Konturek SJ, Kwiecien N, Obtulowicz W, Oleksy J, Sito E, Kopp B (1984) Scand J Gastroenterol Suppl. 92:250–254PubMedGoogle Scholar
  6. 6.
    Müller-Peddinghaus R, Wurl M (1987) Biochem Pharmacol 36:1.125–1.132CrossRefGoogle Scholar
  7. 7.
    Crevoisier C (1982) Eur J Rheumatol Inflamm 5:492–502PubMedGoogle Scholar
  8. 8.
    Iwakawa S, Spahn H, Benet LZ, Lin ET (1990) Biochem Pharmacol 39:949–953PubMedCrossRefGoogle Scholar
  9. 9.
    Rubio F, Seawall S, Pocelinko E, De Barbieri B, Benz W, Berger L, Morgan L, Pao J, Williams TH, Koechlin B(1980) J Pharm Sci 69:1.245–1.253CrossRefGoogle Scholar
  10. 10.
    Stoltenborg JK, Puglisi CV, Rubio F, Vane FM (1981) J Pharm Sci 70:1.207–1.212CrossRefGoogle Scholar
  11. 11.
    Przybilla B, Ring J, Schwab U, Galosi A, Dorn M, Braun-Falco O (1987) Hautarzt 38:18–25PubMedGoogle Scholar
  12. 12.
    Przybilla B, Schwab-Przybilla U, Ruzicka T, Ring J (1987) Photodermatol 4:73–78PubMedGoogle Scholar

Hs/KA

  1. 1.
    Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge New Jersey USA, S.256Google Scholar
  2. 2.
    Takeshita Y, Mizukami K (1991) Jp Kokai Tokkyo Koho Jp 0377,870; zit. nach CA (1991) 115:135939bGoogle Scholar
  3. 3.
    Winkler W (1983) Arszneim Forsch 33:279Google Scholar
  4. 4.
    Tsuda Y, Yoshimoto K, Nishikawa T (1981) Chem Pharm Bull 29:3593CrossRefGoogle Scholar
  5. 5.
    Nieder M, Strösser W, Kappler J (1987) Arzneim Forsch 37:549Google Scholar
  6. 6.
    Schütz H, Meister T (1990) Arzneim Forsch 40:651Google Scholar

RE

  1. 1.
    Odenthal KP (1983) Arzneim Forsch 33(I):281–285Google Scholar
  2. 2.
    Koike K, Takayanagi I (1983) Jap J Pharmacol 33:327–333PubMedCrossRefGoogle Scholar
  3. 3.
    Kuwahara M, Amano H, Kubo T, Miso Y (1987) Jap J Pharmacol 43:445–448PubMedCrossRefGoogle Scholar
  4. 4.
    Ohno K, Nakamura S, Goshima Y, Misu Y (1990) Jap J Pharmacol 52:643–646PubMedCrossRefGoogle Scholar
  5. 5.
    Takayanagi I, Ogishima M, Koike K, Hisayama T, Hayashida M (1989) Gen Pharmacol 20:417–419PubMedCrossRefGoogle Scholar
  6. 6.
    Small M, Douglas JT, Aherne GW, Orr M, Lowe GD, Forbes CD, Prentice CR (1982) Thromb Res 25:351–360PubMedCrossRefGoogle Scholar
  7. 7.
    Lorenz D (1983) Arzneim Forsch 33(I):296–304Google Scholar
  8. 8.
    Ishizaki T, Ohnishi A, Sasaki T, Kushida K, Horai Y, Chiba K, Suganuma T (1983) Eur J Clin Pharmacol 25:95–101PubMedCrossRefGoogle Scholar
  9. 9.
    Schloos J, Pitschner HF, Wellstein A, Palm D, Belz GG, Mutschier E (1990) Zusammenhang zwischen Pharmakokinetik und Pharmakodynamik der Beta-Rezeptorenblocker. In: Follath F (Hrsg.) Neue Aspeke der Betablocker-Therapie, Gustav Fischer Verlag, Stuttgart, S. 21–38Google Scholar
  10. 10.
    Nishio H, Nagakura Y, Segawa T (1989) Arch Int Pharmacodyn Ther 302:96–106PubMedGoogle Scholar
  11. 11.
    Schnaudigel OE, Becker H, Fuchs HB (1988) Klin Monatsbl Augenheilkd 192:248–251PubMedCrossRefGoogle Scholar
  12. 12.
    Scoville B, Mueller B, White BG, Krieglstein GK (1988) Am J Ophthalmol 105:150–154PubMedGoogle Scholar
  13. 13.
    Le-Jeunne C, Munera Y, Hugues FC (1990) Clin Pharmacol Ther 47:578–583PubMedCrossRefGoogle Scholar

PH

  1. 1.
    Winkler W (1983) Arzneim Forsch 33:279Google Scholar
  2. 2.
    Zoelss G, Pfanhofer G (1987) Lentia GmbH, Ger Offen DE 3,544,172, zit. nach CA (1987) 107:242.599xGoogle Scholar
  3. 3.
    Drug Fut (1977) 2:288Google Scholar

RE

  1. 1.
    Tsuda Y, Yoshimoto K, Nishikawa T (1981) Chem Pharm Bull 29:3593CrossRefGoogle Scholar
  2. 2.
    Ohwa M, Akiyoshi M, Mitamura S (1990) J Chromatogr 521:122PubMedCrossRefGoogle Scholar

RE

  1. 1.
    Tsuda Y, Yoshimoto K, Nishikawa T (1981) Chem Pharm Bull 29:3593CrossRefGoogle Scholar
  2. 2.
    Ohwa M,Akiyoshi M, Mitamura S (1990) J Chromatogr 521:122PubMedCrossRefGoogle Scholar

RE

  1. 1.
    Sendai M et al (1985) J Antibiotics 38:346–371CrossRefGoogle Scholar
  2. 2.
    Kishimoto S et al (1983) J Antibiotics 36:1421–1424CrossRefGoogle Scholar

Gd

  1. 1.
    Mar 29, S. 142Google Scholar

vB

  1. 1.
    Taheda Chemical Ind. Ltd., InformationsschriftGoogle Scholar
  2. 2.
    Drugs Fut (1985) 10: 967–971Google Scholar

Gd

  1. 1.
    Ritter JJ, Ginsburg D (1950) J Am Chem Soc 72:2381–2384CrossRefGoogle Scholar
  2. 2.
    Strubell W, Baumgärtel H (1958) Arch Pharm 291:66–67CrossRefGoogle Scholar

My/Ms

  1. 1.
    Reitsema RH (1958) J Org Chem 23:2038CrossRefGoogle Scholar
  2. 2.
    Swigar AA, Silverstein RM (1981) Monoterpenes, Aldrich Chem Comp IncGoogle Scholar
  3. 3.
    Bohlmann F, Zeisberg R, Klein E (1975) Org Magn Res 7:426–432CrossRefGoogle Scholar
  4. 4.
    Brockelt G, Pohloudek-Fabini R (1959) Pharmazeutische Zentralhalle 98:499Google Scholar

My/Ms

  1. 1.
    Ehrhart G, Ruschig H (1972) Arzneimittel, Bd. III, Verlag Chemie GmbH, Weinheim, Bergstraße, S. 111Google Scholar
  2. 2.
    Andersen KE (1978) Contact Dermatitis 4:195–198PubMedCrossRefGoogle Scholar
  3. 3.
    Shirley SG, Robinson CJ, Dickinson K, Aujla R, Dodd GH (1986) Biochem J 240:605–607PubMedGoogle Scholar
  4. 4.
    Sklar PB, Anholt RRH, Snyder SH (1986) J Biol Chem 261:15.538–15.543Google Scholar
  5. 5.
    Dreesen TD, Koch RB (1982) Biochem J 203:69–75PubMedGoogle Scholar
  6. 6.
    Göckeritz D, Weufen W, Höppe H (1974) Pharmazie 29:339–344PubMedGoogle Scholar
  7. 7.
    Ishida T, Toyota M, Asakawa Y (1989) Xenobiotica 19:843–855PubMedCrossRefGoogle Scholar
  8. 8.
    Braga PC, De Angelis L, Bossi R, Scaglione F, Scarpazza G, Allegra L, Fraschini F (1983) Eur J Clin Pharmacol 24:209–215PubMedCrossRefGoogle Scholar
  9. 9.
    Patton DW, Ferguson MM, Forsyth A, James J (1985) Br J Oral Maxillofac Surg 23:235–242PubMedCrossRefGoogle Scholar

PK

  1. 1.
    Stempel GH Jr, Schaffei GS (1944) J Am Chem Soc 66:1158–1159CrossRefGoogle Scholar

My/Ms

  1. 1.
    Mar 29, S. 1.061–1.067Google Scholar
  2. 2.
    MI, S. 1.856Google Scholar
  3. 3.
    Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, BerlinGoogle Scholar

vB

  1. 1.
    Goldberg AA, Wragg AH (1960) J Chem Soc:1408–1409Google Scholar
  2. 2.
    Feichtinger H (1971) Chem Ber 104:1697–1698CrossRefGoogle Scholar
  3. 3.
    Kuhnert-Brandstätter M, Geiler M, Wurian I (1980) Sci Pharm 48:250–258Google Scholar
  4. 4.
    Frank H, Heinisch G, Rank W (1979) Sci Pharm 47:135–142Google Scholar
  5. 5.
    Szokolay AM (1980) J Chromatogr 187:249–254CrossRefGoogle Scholar
  6. 1.
    Beyer KH (1954) Arch Int Pharmakodynm Ther 98:97–117Google Scholar
  7. 2.
    Beyer KH, Baer JE (1961) Pharmacol Rev 13:517–562PubMedGoogle Scholar
  8. 3.
    De Stevens G (1963) Diuretics Chemistry and Pharmacology-Sulfonamides, Academic Press, New York London, S.47ffGoogle Scholar
  9. 4.
    Ford RW, Spurr CL, Moyer JH (1957) Circulation 16:394–398PubMedCrossRefGoogle Scholar
  10. 5.
    Beyer KH (1977) J Clin Pharmacol 17:618–625PubMedGoogle Scholar
  11. 6.
    Peter G, Roch-Ramel F (1969) Thiazine diuretics and related drugs. In: Eichler O, Farah A, Herken H, Welch AD (Hrsg.) Handbuch der experimentellen Pharmakologie, 24 (Diuretica), Springer Verlag, Berlin Heidelberg New York, S. 257–355Google Scholar
  12. 7.
    Feit PW (1981) J Clin Pharmacol 21:531–536PubMedCrossRefGoogle Scholar
  13. 8.
    Ferguson EB (1951) J Physiol 112:420–425PubMedGoogle Scholar
  14. 9.
    Crosley AP Jr, Rowe GG (1955) Proc Soc Exp Biol Med 89:26–28PubMedGoogle Scholar
  15. 10.
    Price GH (1979) Clin Chim Acta 94:211–217PubMedCrossRefGoogle Scholar
  16. 11.
    Merrill JP (1953) Am J Med 16:519Google Scholar
  17. 12.
    Pirn EJ (1939) Med Welt 13:706Google Scholar
  18. 13.
    Oettel H, Bachmann H (1936) Arch exp Path Pharmakol 183:159–169CrossRefGoogle Scholar
  19. 14.
    Ball LM, Renwick AG, Williams RT (1977) Xenobiotica 7:189–203PubMedCrossRefGoogle Scholar
  20. 15.
    Hartles RL, Williams RT (1947) Biochem J 41:206–212Google Scholar
  21. 16.
    Ball LM, Williams RT, Renwick AG (1978) Xenobiotica 8:183–190PubMedCrossRefGoogle Scholar
  22. 17.
    Minack TH(1987) Mnch Med Wochenschr 19:366–367Google Scholar
  23. 18.
    Lindsay AE, Brown H (1954) J Lab Clin Med 43:839–847 KCPubMedGoogle Scholar
  24. 19.
    Schorno HX (1982) Pharm Unserer Zeit 11:65–73PubMedCrossRefGoogle Scholar
  25. 20.
    Pfanz H, Wieduwilt H (1955) Arch Pharm 288:563–82; Pfanz H, Wieduwilt H Anm.(1956) DDR-P 13785CrossRefGoogle Scholar
  26. 21.
    Rebstock MC, Moersch GW, Moore AC, Vanderbelt JM (1951) J Am Soc 73:3666–3670CrossRefGoogle Scholar
  27. 4.
    Heacock RA, Forrest JE (1974) Can J Pharm Sci 9:64Google Scholar
  28. 5.
    Nagai WN,Kanao S (1929) Liebigs Ann Chem 470:157–182CrossRefGoogle Scholar
  29. 6.
    Wolfes O (1930) Arch Pharm 268:81–83CrossRefGoogle Scholar
  30. 7.
    Firmenschrift Knoll AG (1977): Pharma ChemikalienGoogle Scholar
  31. 8.
    Steinigen M (1973) Dtsch Apoth Ztg 113(3):81–92Google Scholar
  32. 9.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, 2nd Ed. The Pharmaceutical Press, LondonGoogle Scholar
  33. 10.
    Heiden PG (1986) unveröffentlicht; vgl. auch Testa B (1973) Pharm Acta Helv 48:389–398Google Scholar
  34. 11.
    Neuninger H (1987) Sci Pharm 55:1–11Google Scholar
  35. 12.
    Kovar KA, Noy M, Pieper R (1982) Dtsch Apoth Ztg 122:3–22Google Scholar
  36. 13.
    Meyer J, Portmann P (1982) Pharm Acta Helv 57(1):12–15PubMedGoogle Scholar
  37. 14.
    Klein H, Teichmann R (1982) Pharm Ztg 127(8):447–451Google Scholar
  38. 15.
    Wollmann H, Gruenert R, Senf HJ, Raether G, Schlosser H (1980) Pharmazie 35:120PubMedGoogle Scholar

NE

  1. 1.
    Mar 29, S. 1.555Google Scholar

vB

  1. 1.
    Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, LondonGoogle Scholar

NE

  1. 1.
    BAz, Nr. 190a vom 10.10.1985Google Scholar

GS

  1. 1.
    Synth. MerckGoogle Scholar
  2. 2.
    Herstellerangaben aus “Standardinformationen für Krankenhausapotheker”Google Scholar
  3. 3.
    Neu H (1972) J Antibiotics 25:400CrossRefGoogle Scholar

Gg

  1. 1.
    Mar 29, S. 173Google Scholar

vB

  1. 1.
    Neth Appl 6600586 (CIBA, 1965), zit. nach CA (1966) 65:20131Google Scholar
  2. 2.
    Itoh H, Shinbori Y, Tamura N (1983) Bunseki Kagaku 32 (10):571–575, zit. nach CA (1984) 100:56918fCrossRefGoogle Scholar
  3. 3.
    Adamovics JA: Cromatographic Analysis of Pharmaceuticals (1990), Chromatographic Science Series (1990), Dekker Inc. New York 49:289Google Scholar
  4. 4.
    Barbato F, Bava A, Grieco C, Silipo C, Vittoria A (1978) Ann Chim (Rom), 68 (7–8):575–583, zit nach CA (1979) 90:210193zGoogle Scholar
  5. 5.
    Casalini C, Ceserano G, Mascellani G (1977) Anal Chem 49(7):1002–1004, zit. nach CA (1977) 86:195240jCrossRefGoogle Scholar
  6. 6.
    Koshiro A, Fujita T (1982) Bull Yamaguchi Med Sch 29 (3–4) 85–92, zit nach CA (1983) 99:110575tGoogle Scholar

mh

  1. 1.
    Herstellerangaben aus “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Bill NJ, Washington JA II (1977) Antimicrob Agents Chemother 11:470–474PubMedCrossRefGoogle Scholar
  2. 2.
    Neu HC, Fu KP (1978) Antimicrob Agents Chemother 13:584–588PubMedCrossRefGoogle Scholar
  3. 3.
    Riess W, Meyer-Brunot HG, Brechbühler S (1982) Pharmakokinetik oraler Cephalosporine. In: Adam D, Grobecker H, Naber KG (Hrsg.) Cephalosporine der 80er Jahre, FAC (Fortschritte der Antimikrobiellen-Antineoplastischen Chemotherapie) 1–1:115–131Google Scholar
  4. 4.
    Daten der Firma Eli Lilly (s. Fachinformation zu Panoral®)Google Scholar
  5. 5.
    Rotschafer JC, Crossley KB, Lesar TS, Zaske D, Miller K (1982) Antimicrob Agents Chemother 21:170–172PubMedCrossRefGoogle Scholar
  6. 6.
    Hodges GR, Liu C, Hinthorn DR, Harms JL, Dworzack DL (1978) Antimicrob Agents Chemother 14:454–456PubMedCrossRefGoogle Scholar
  7. 7.
    Meyers BR, Hirschman SZ, Wormser G, Gartenberg G, Srulevitch E (1978) J Clin Pharmacol 18:174–179PubMedCrossRefGoogle Scholar
  8. 8.
    Korzeniowski OM, Scheid WM, Sande MA (1977) Antimicrob Agents Chemother 12:157–162PubMedCrossRefGoogle Scholar
  9. 9.
    McCracken GH Jr, Ginsburg CM, Clahsen JC, Thomas ML (1978) J Antimicrob Chemother 4:515–521PubMedCrossRefGoogle Scholar
  10. 10.
    Oguma T, Yamada H, Sawaki M, Narita N (1991) Antimicrob Agents Chemother 35:1.729–1.735CrossRefGoogle Scholar
  11. 11.
    Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Pittman KA (1990) Antimicrob Agents Chemother 34:1.210–1.213Google Scholar
  12. 12.
    Bergan T (1987) Drugs 34(Suppl.2):89–104PubMedCrossRefGoogle Scholar
  13. 13.
    Santoro J, Agarwal BN, Martinelli R, Wenger N, Levison ME (1978) Antimicrob Agents Chemother 13:951–954PubMedCrossRefGoogle Scholar
  14. 14.
    Bloch R, Szwed JJ, Sloan RS, Luft FC (1977) Antimicrob Agents Chemother 12:730–732PubMedCrossRefGoogle Scholar
  15. 15.
    Meyers BR, Hirschmann SZ (1978) J Clin Pharmacol 18:85–90PubMedCrossRefGoogle Scholar
  16. 16.
    Sanders CC (1977) Antimicrob Agents Chemother 12:490–497PubMedCrossRefGoogle Scholar
  17. 17.
    Bach VT, Khurana MM, Thadepalli H (1978) Antimicrob Agents Chemother 13:210–213PubMedCrossRefGoogle Scholar

CW

  1. 1.
    Mitteilung der Bristol-Arzneimittel GmbH MünchenGoogle Scholar

Gg

  1. 1.
    Monographie: Cefadroxil, BAz Nr. 222 vom 30.11.1991, Jg. 43,7.732Google Scholar
  2. 2.
    Tanrisever B, Santella PJ (1986) Drugs 32 (Suppl 3):1–16PubMedCrossRefGoogle Scholar
  3. 3.
    Henness DM, Richards D (1978) Clin Therapeutics 1:263–273Google Scholar
  4. 4.
    Riess W, Meyer-Brunot HG, Brechenbühler S (1982) Pharmakokinetik oraler Cephalosporine. In: Adam D, Grobecker H, Naber KG (Hrsg.) Cephalosporine der 80er Jahre, FAC (Fortschritte der Antimikrobiellen-Antineoplastischen Chemotherapie) 1–1:115–131Google Scholar
  5. 5.
    Lode H, Stahlmann R, Dzwillo G, Koeppe P (1980) Arzneim Forsch 30:505–509Google Scholar
  6. 6.
    Simon C (1980) Arzneim Forsch 30:502–504Google Scholar
  7. 7.
    Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF (1991) Eur J Clin Pharmacol 41:179–183PubMedCrossRefGoogle Scholar
  8. 8.
    Bergan T (1987) Drugs 34 (Suppl 2):89–104PubMedCrossRefGoogle Scholar
  9. 9.
    Wise R (1990) J Antimicrob Chemother 26 (Suppl E):13–20PubMedCrossRefGoogle Scholar
  10. 10.
    Cutler RE, Blair AD, Kelly MR (1979) Clin Pharmacol Ther 25:514–521PubMedGoogle Scholar
  11. 11.
    Degen J, Ringwelski L, Maier-Lenz H (1983) Arzneim Forsch 33:1.339–1.342Google Scholar

CW

  1. 1.
    Herstellerangaben aus “Standardinformationen für Krankenhausapotheker”Google Scholar
  2. 1.
    Weinstein AJ (1980) Drugs 19:137–154CrossRefGoogle Scholar
  3. 2.
    Gentry LO (1987) Drugs 34 (Suppl 2):154–163PubMedCrossRefGoogle Scholar
  4. 3.
    Riess W, Meyer-Brunot HG, Brechbühler S (1982) Pharmakokinetik oraler Cephalosporine. In: Adam D, Grobecker H, Naber KG (Hrsg.) Cephalosporine der 80er Jahre, FAC (Fortschritte der Antimikrobiellen-Antineoplastischen Chemotherapie) 1–1:115–131Google Scholar
  5. 4.
    Brogard JM, Pinget M, Dorner M, Lavillaureix J (1975) J Clin Pharmacol 15:666–673PubMedCrossRefGoogle Scholar
  6. 5.
    Lode H, Stahlmann R, Dzwillo G, Koeppe P (1980) Arzneim Forsch 30/I:505–509Google Scholar
  7. 6.
    Pfeffer M, Jackson A, Ximenes J, Perche de Menezes J (1977) Antimicrob Agents Chemother 11:331–338PubMedCrossRefGoogle Scholar
  8. 7.
    Monographie: Cephalexin, BAz Nr. 13 vom 19.1.1991, Jg. 43, S. 303–304Google Scholar
  9. 8.
    Tanrisever B, Santella PJ (1986) Drugs 32 (Suppl 3):1–16PubMedCrossRefGoogle Scholar
  10. 9.
    Bergan T (1987) Drugs 34 (Suppl 2):89–104PubMedCrossRefGoogle Scholar
  11. 10.
    Wise R (1990) J Antimicrob Chemother 26 (Suppl E):13–20PubMedCrossRefGoogle Scholar
  12. 11.
    Hadorn K, Kayser FH (1987) Antibakterielle Aktivität von Cefixim im Vergleich mit oralen Cephalosporinen und weiteren Antibiotika. In: Stille W, Adam D (Hrsg.) Neue Cephalosporine, FAC (Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie) 6–8:1.213–1.222Google Scholar

CW

  1. 1.
    Herstellerangaben aus “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Mar 29, S. 175Google Scholar

vB

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Monographie: Cephaloridin, BAz Nr. 148 vom 10.08.1991, Jg 43:5.356Google Scholar
  2. 2.
    Bergan T (1987) Drugs 34 (Suppl.2):89–104PubMedCrossRefGoogle Scholar
  3. 3.
    Weinstein AJ (1980) Drugs 19:137–154CrossRefGoogle Scholar
  4. 4.
    Cephalothin and Cephaloridine. In: Kucers A, Bennett NMcK (Hrsg.) The use of antibiotics, William Heine mann Medical Books Ltd., 3. Aufl. 1979, S. 199–224Google Scholar
  5. 5.
    Norrby SR (1987) Drugs 34 (Suppl. 2):105–120PubMedCrossRefGoogle Scholar
  6. 6.
    Foord RD (1975) J Antimicrob Chemother 1 (Suppl):119–133PubMedCrossRefGoogle Scholar
  7. 7.
    Wachsmuth ED (1982) Toxicol Appl Pharmacol 63:446–460PubMedCrossRefGoogle Scholar
  8. 8.
    Wachsmuth ED (1982) Toxicol Appl Pharmacol 63:429–445PubMedCrossRefGoogle Scholar
  9. 9.
    Tune BM, Fravert D, Hsu C-Y (1989) Biochem Pharmacol 38:795–802PubMedCrossRefGoogle Scholar
  10. 10.
    Kramer W, Cojocel C, Mayer D (1988) Biochem Pharmacol 37:4.135–4.140Google Scholar
  11. 11.
    Tune BM, Wu KYW, Kempson RL (1977) J Pharmacol Exptl Ther 202:466–471Google Scholar

CW

  1. 1.
    HerstellerangabenGoogle Scholar

Gg

  1. 1.
    Rolewicz TF, Mirkin BL, Cooper MJ, Anders MW (1977) Clin Pharmacol Ther 22:92–935Google Scholar
  2. 2.
    Weinstein AJ (1980) Drugs 19:137–154CrossRefGoogle Scholar
  3. 3.
    Sosna JP, Murray PR, Medoff G (1978) Antimicrob Agents Chemother 14:876–879PubMedCrossRefGoogle Scholar
  4. 4.
    Tan JS, Salstrom SJ (1977) Antimicrob Agents Chemother 11:698–700PubMedCrossRefGoogle Scholar
  5. 5.
    Sabath LD (1989) Antimicrob Agents Chemother 33:407–411PubMedCrossRefGoogle Scholar
  6. 6.
    Monographie: Cephalothin, BAZ, Nr. 15 vom 23. Januar 1991, Jg43:S341Google Scholar
  7. 7.
    Turck M, Anderson KN, Smith RH, Wallace JF, Petersdorf R (1965) Ann Intern Med 63:199–211PubMedCrossRefGoogle Scholar
  8. 8.
    Rattie ES, Ravin LJ (1975) Antimicrob Agents Chemother 7:606–613PubMedCrossRefGoogle Scholar
  9. 9.
    Bergan T (1977) Chemotherapy (Basel) 23:389–404CrossRefGoogle Scholar
  10. 10.
    Gump DW, Lipson RL (1968) Curr Ther Res 10:583–591PubMedGoogle Scholar
  11. 11.
    Ratzan KR, Baker HB, Lauredo I (1978) Antimicrob Agents Chemother 13:985–987PubMedCrossRefGoogle Scholar
  12. 12.
    Vianna NJ, Kaye D (1967) Am J Med Sci 254:216–220PubMedCrossRefGoogle Scholar
  13. 13.
    Mangi RJ, Kundargi RS, Quintiliani R, Andriole VT (1973) Ann Intern Med 78:347–351PubMedCrossRefGoogle Scholar
  14. 14.
    Morrow S, Palmisano P, Cassady G (1968) J Pediatrics 73:262–264CrossRefGoogle Scholar
  15. 15.
    Bergan T (1987) Drugs 34(Suppl.2):89–104PubMedCrossRefGoogle Scholar
  16. 16.
    Buhs RP, Maxim TE, Allen N, Jacob T, Wolf FJ (1974) J Chromatog 99:609–618CrossRefGoogle Scholar
  17. 17.
    Bergeron MG, Brusch JL, Barza M, Weinstein L (1976) Antimicrob Agenbts Chemother 9:646–650CrossRefGoogle Scholar
  18. 18.
    Ram MD (1974) Arch Surgery 108:187–191CrossRefGoogle Scholar
  19. 19.
    Kunin CM, Atuk N (1966) N Engl J Med 274:654–656PubMedCrossRefGoogle Scholar

CW

  1. 1.
    HerstellerangabenGoogle Scholar

Gg

  1. 1.
    Weinstein AJ (1980) Drugs 19:137–154CrossRefGoogle Scholar
  2. 2.
    Neu HC (1974) Antimcrob Agents Chemother 6:177–182CrossRefGoogle Scholar
  3. 3.
    Eickhoff TC, Ehret JM (1976) Antimicrob Agents Chemother 9:994–999PubMedCrossRefGoogle Scholar
  4. 4.
    Monograph: Cefamandol, BAz, Nr. 13 vom 19. Januar 1991 91 Jg 43:302–303Google Scholar
  5. 5.
    Kaiser GV, Gorman M, Webber JA (1978) J Infect Dis 137(SupplMay):S10–S16PubMedCrossRefGoogle Scholar
  6. 6.
    Richmond MH (1980) Scand J Infect Dis (Suppl.25):11–16Google Scholar
  7. 7.
    Griffiths RS, Black HR, Brier GL, Wolny JD (1976) Antimicrob Agents Chemother 10:814–823CrossRefGoogle Scholar
  8. 8.
    Sabath LD (1989) Antimicrob Agents Chemother 33:407–411PubMedCrossRefGoogle Scholar
  9. 9.
    Meilin HE, Welling PG, Madsen PO (1977) Antimicrob Agents Chemother 11:262–266CrossRefGoogle Scholar
  10. 10.
    Grose WE, Bodey GP, Stewart D (1976) Clin Pharmacol Ther 20:579–684PubMedGoogle Scholar
  11. 11.
    Neu HC (1980) Scand J Infect Dis (Suppl. 25):39–44Google Scholar
  12. 12.
    Daten der Firma Eli Lilly (s. Fachinformation zu Mandokef®)Google Scholar
  13. 13.
    Stahlmann R, Chahoud J (1986) Krankenhauspharmazie 7:270–272Google Scholar
  14. 14.
    Leigh DA, Marriner J, Nisbet D, Powell HDW, Church JCT, Wise K (1982) J Antimicrob Chemother 9:303–311PubMedCrossRefGoogle Scholar
  15. 15.
    Ratzan KR, Baker HB, Lauredo I (1978) Antimicrob Agents Chemother 13:985–987PubMedCrossRefGoogle Scholar
  16. 16.
    Korzeniowski OM, Carvelho EM, Rocha H, Sande MA (1978) J Infect Dis 137(Suppl May):S169–S179PubMedCrossRefGoogle Scholar
  17. 17.
    Bergan T (1987) Drugs 34(Suppl.2):89–104PubMedCrossRefGoogle Scholar
  18. 18.
    Meyers BR, Ribner B, Yancovitz S, Hirschmann SZ (1976) Antimicrob Agents Chemother 9:140–144PubMedCrossRefGoogle Scholar
  19. 19.
    Sullivan HR, Due SL, Kau DLK, Quay JF, Miller WM (1979) Antimicrob Agents Chemother 12:73–79CrossRefGoogle Scholar
  20. 20.
    Agbayani MM, Khan AJ, Kemawikasit P, Rosenfeld W, Salazar D, Kumar K, Glass L, Evans HE (1979) Antimicrob Agents Chemother 15:674–676PubMedCrossRefGoogle Scholar
  21. 21.
    Arbeitsgemeinschaft Arzneimittelsicherheit der PaulEhrlich-Gesellschaft für Chemotherapie e.V. (1984) Dtsch Ärztebl 81:3.823–3.824Google Scholar
  22. 22.
    Bechtold H, Andrassy K (1988) Hämostaseologie 8:8–17Google Scholar
  23. 23.
    Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jähnchen E, Ritz E (1988) J Clin Pharmacol 28:88–95PubMedCrossRefGoogle Scholar
  24. 24.
    Hooper CA, Haney BB, Stone HH (1980) Lancet 1980/i:39–40CrossRefGoogle Scholar
  25. 25.
    Clancy CM, Glew RH (1983) Lancet 1983/i:250CrossRefGoogle Scholar
  26. 26.
    Shevchuk YM, Conly JM (1990) Rev Infect Dis 12:1.109–1.126CrossRefGoogle Scholar

CW

  1. 1.
    Crast Jr LB, Graham RG, Cheney LC (1973) J Med Chem 16:1413–1415PubMedCrossRefGoogle Scholar
  2. 1.
    Mar 29, S. 144Google Scholar

vB

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar
  2. 2.
    Gericke R, Rogalski W (1979) Arzneim Forsch 29:362–369Google Scholar

Gg

  1. 1.
    Arbeitsgemeinschaft Arzneimittelsicherheit der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (1989) Dtsch Abl 86:492–493Google Scholar
  2. 2.
    Bechtold H, Andrassy K (1988) Hämostaseologie 8:8–17Google Scholar
  3. 3.
    Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jähnchen E, Ritz E (1988) J Clin Pharmacol 28:88–95PubMedCrossRefGoogle Scholar
  4. 4.
    Monographie: Cefazedon, BAz Nr. 222 vom 30.11.1991, Jg. 43, S. 7.730Google Scholar
  5. 5.
    Wahlig H, Dingeldein E, Mitsuhashi S, Kawabe H (1979) Arzneim Forsch 29:369–378Google Scholar
  6. 6.
    Werner H, Krasemann C, Ungerechts J (1979) Arzneim Forsch 29:388–392Google Scholar
  7. 7.
    Russell AD, Rogers DT (1980) J Antimicrob Chemother 6:288–292PubMedCrossRefGoogle Scholar
  8. 8.
    Pabst J, Leopold G, Ungethüm W, Dingeldein E (1979) Arzneim Forsch 29:437–443Google Scholar
  9. 9.
    Pabst J, Leopold G, Ungethüm W, Dingeldein E (1979) Arzneim Forsch 29:443–448Google Scholar
  10. 10.
    Züllich B, Sack K (1979) Arzneim Forsch 29:453–456Google Scholar
  11. 11.
    Koch E, Friese J, Debuch KE (1979) Arzneim Forsch 29:456–460Google Scholar
  12. 12.
    Daten der Firma E. Merck (s. Fachinfo zu Refosporin®)Google Scholar
  13. 13.
    Brogard JM, Comte F (1982) Pharmacokinetics of the new cephalosporins. In: Schönfeld H (Hrsg.) Antibiotics and Chemotherapy; Pharmacokinetics II, Bd.31, Karger, Basel, S. 145–210Google Scholar

CW

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar
  2. 2.
    Palomo Coll A, Palomo AL (1985) Tetrahedron Lett 41:5133–5139CrossRefGoogle Scholar
  3. 3.
    Tori K, Nishikawa J, Takeuchi Y (1981) Tetrahedron Lett. 22:2793–2796CrossRefGoogle Scholar

Gg

  1. 1.
    Sabath LD (1989) Antimicrob Agents Chemother 33:407–411PubMedCrossRefGoogle Scholar
  2. 2.
    Weinstein AJ (1980) Drugs 19:137–154CrossRefGoogle Scholar
  3. 3.
    Monographie: Cephazolin, BAz, Nr. 13 vom 19. Januar 1991, Jg 43:304Google Scholar
  4. 4.
    Bassaris HP, Quintiliani R, Maderazo EG, Tilton RC, Nightingale CH (1976) Curr Ther Res 19:110–120PubMedGoogle Scholar
  5. 5.
    Bergan T (1977) Chemotherapy (Basel) 23:389–404CrossRefGoogle Scholar
  6. 6.
    Rattie ES, Ravin LJ (1975) Antimicrob Agents Chemother 7:606–613PubMedCrossRefGoogle Scholar
  7. 7.
    Cole DR, Pung J (1977) Antimicrob Agents Chemother 11:1.033–1.035CrossRefGoogle Scholar
  8. 8.
    Ratzan KR, Baker HB, Lauredo I (1978) Antimicrob Agents Chemother 13:985–987PubMedCrossRefGoogle Scholar
  9. 9.
    Brogard J, Dorner M, Pingeet M, Adlott M, Lavillaureix(1975) J Infect Dis 131:625–633PubMedCrossRefGoogle Scholar
  10. 10.
    Gold SA, McKee JJ, Zio DS (1973) J Infect Dis 128(Suppl.):S415–421PubMedCrossRefGoogle Scholar
  11. 11.
    Bergan T (1987) Drugs 34(Suppl.2):89–l04PubMedCrossRefGoogle Scholar
  12. 12.
    Quintiliani R, Nightingale CH (1978) Ann Intern Med 89:650–656PubMedCrossRefGoogle Scholar
  13. 13.
    Bergan T, Brodwall EK, Orjarik O (1977) Antimicrob Agents Chemother 3:435–444CrossRefGoogle Scholar
  14. 14.
    Madhavan T, Yaremchuk K, Levin N, Fisher E, Cox F, Burch K, Haas E, Pohlod D, Quinn EL (1975) Antimicrob Agents Chemother 8:63–66PubMedCrossRefGoogle Scholar
  15. 15.
    Arbeitsgemeinschaft Arzneimittelsicherheit der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (1989) Dtsch Ärztebl. 86:492–493Google Scholar
  16. 16.
    Bechtold H, Andrassy K (1988) Hämostaseologie 8:8–17Google Scholar
  17. 17.
    Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jähnchen E, Ritz E (1988) J Clin Pharmacol 28:88–95PubMedCrossRefGoogle Scholar

cw

  1. 1.
    Herstellerangaben aus “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar
  2. 2.
    Yamanaka H et al (1985) J Antibiot 33:1738–1751CrossRefGoogle Scholar

Gg

  1. 1.
    Brogden RN, Campoli-Richards DM (1989) Drugs 38:524–550PubMedCrossRefGoogle Scholar
  2. 2.
    Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AJ, Yacobi A, Silber BM (1988) J Clin Pharmacol 28:700–706PubMedCrossRefGoogle Scholar
  3. 3.
    Daten der Firma Merck (s. die Fachinformation zu Cephoral®)Google Scholar
  4. 4.
    Brittain DC, Scully BE, Hirose T, Neu HC (1985) Clin Pharmacol Ther 38:590–594PubMedCrossRefGoogle Scholar

cw

  1. 1.
    Herstellerangaben aus “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Campoli-Richards DM, Todd PA (1987) Drugs 34:188–221PubMedCrossRefGoogle Scholar
  2. 2.
    Labia R, Morand A, Ben Yaghlane H, Bryskier A (1985) Drugs Exptl Clin Res XI:373–378Google Scholar
  3. 3.
    Verschiedene Autoren (1983) In: Adam D, Stille W, Ullmann U (Hrsg.) Cefmenoxim, FAC (Fortschritt der Antimikrobiellen-Antineoplastischen Chemotherapie), Futuramed Verlag, München, 2–2:187–411Google Scholar
  4. 4.
    Barriere SL, Flaherty JF (1984) Clin Pharm 3:351–373PubMedGoogle Scholar
  5. 5.
    Anonymer Autor (1986) Mikrobiologie und Pharmakokinetik parenteraler Cephalosporine. Broschüre, Hofmann-LaRoche, S. 1–37Google Scholar
  6. 6.
    Daten der Firma Takeda (s. Fachinformation zu Tacef®).Google Scholar
  7. 7.
    Stoeckel K (1982) FAC (Fortschritt der Antimikrobiellen und Antineoplastischen Chemotherapie) 11:105–113Google Scholar
  8. 8.
    Naber K, Adam D, Kees F, Lintz W, Grobecker H (1983) FAC (Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie) 2–2:297–313Google Scholar
  9. 9.
    Balant L, Dayer P, Auckenthaler R (1985) Clin Pharmacokinet 10:101–143PubMedCrossRefGoogle Scholar
  10. 10.
    Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jähnchen E, Ritz E (1988) J Clin Pharmacol 28:88–95PubMedCrossRefGoogle Scholar

cw

  1. 1.
    Daten der Firma Hoechst (s. dazu Fachinformation zu Modivid®).Google Scholar
  2. 2.
    Dagrosa EE, Hajdu P, Malerczyk V, de Looze S, Seeger K, Grötsch H (1987) Clin Therapeut 10:18–31Google Scholar
  3. 3.
    Schäfer-Korting M, Korting HC, Maass L, Kiesel N, Grigoleit HG, Mutschier E (1986) Eur J Clin Pharmacol 30:295–298PubMedCrossRefGoogle Scholar
  4. 4.
    Barradell LB, Brogden RN (1992) Drugs 44: 800–834PubMedCrossRefGoogle Scholar

cw

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS (1981) Drugs 22:423–460PubMedCrossRefGoogle Scholar
  2. 2.
    Fernandes CJ, Stevens DA, Ackerman VP (1985) Chemotherapy (Basel) 31:292–296CrossRefGoogle Scholar
  3. 3.
    Daten der Firma Pfizer (s. Fachinformation zu Cefobis®).Google Scholar
  4. 4.
    Paap CM, Nahata MC (1990) Clin Pharmacokinet 19:280–318PubMedCrossRefGoogle Scholar
  5. 5.
    Balant L, Dayer P, Auckenthaler R (1985) Clin Pharmacokinet 10:101–143PubMedCrossRefGoogle Scholar
  6. 6.
    Anonymer Autor (1986) Mikrobiologie und Pharmakokinetik parenteraler Cephalosporine, Broschüre Hoffmann-LaRoche, S. 1–37Google Scholar
  7. 7.
    Fekety FR (1990) Am J Med 88(Suppl.4A):38–44CrossRefGoogle Scholar
  8. 8.
    Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jähnchen E, Ritz E (1988) J Clin Pharmacol 28:88–95PubMedCrossRefGoogle Scholar

CW

  1. 1.
    Herstellerangaben aus: “Standardinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Herstellerangaben aus “Standarinformationen für Krankenhausapotheker”Google Scholar

Gg

  1. 1.
    Todd PA , Brogden RN(1990) Drugs 40:608–651PubMedCrossRefGoogle Scholar
  2. 2.
    Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS (1983) Drugs 25:223–289PubMedCrossRefGoogle Scholar
  3. 3.
    Ings RMJ, Reeves DS, White LO, Bax RP, Bywater MJ, Holt HA (1985) J Pharmacokin Biopharmaceutics 13:121–142CrossRefGoogle Scholar
  4. 4.
    Ings RM,Fillastre JP, Godin M, Leroy A, Humbert G (1982) Rev Infectious Dis 4 (Suppl):379–391CrossRefGoogle Scholar
  5. 5.
    Balant L, Dayer P, Auckenthaler R (1985) Clin Pharmacokinet 10:101–143PubMedCrossRefGoogle Scholar
  6. 6.
    Paap CM, Nahata MC (1990) Clin Pharmacokinet 19:280–318PubMedCrossRefGoogle Scholar
  7. 7.
    Neu HC (1982) Ann Intern Med 97:408–419PubMedCrossRefGoogle Scholar
  8. 8.
    Christenson J, Squires E, Geiger R, Talbot M (1982) Current Chemother Immunother 1:748–751Google Scholar
  9. 9.
    Then RL, Angehrn P (1982) Antimicrob Agents Chemother 21:711–717PubMedCrossRefGoogle Scholar
  10. 10.
    Jacoby GA, Carreras J (1990) Antimicrob Agents Chemother 34:858–862PubMedCrossRefGoogle Scholar
  11. 11.
    Philippon A, Labia R, Jacoby G (1989) Antimicrob Agents Chemother 33:1.131–1.136CrossRefGoogle Scholar
  12. 12.
    Jacoby GA, Medeiros AA (1991) Antimicrob Agents Chemother 35:1.697–1.704